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OVERVIEW
The research interests of the department in which this study was performed include 
systemic inflammation as a prognostic factor in malignant disease and the role of liver 
blood flow as a prognostic indicator in cancer.  We initially wished to link the liver 
blood flow changes seen in advanced cancer to indicators of systemic inflammation in 
the most inflammed patients in the hospital, the intensive care patients.  Alongside 
scanning the intensive care patients, studies were performed in control, malignant and 
hepatitic patients to corroborate findings of previously published results.  Studies in 
intensive care patients were not able to assess changes in blood flow at the onset of 
illness and a surgical traumatic insult was used as a controlled inflammatory stimuli.
This study was a novel pilot study and it was not possible to perform any power 
calculations, instead similar historical studies were used as a guide as to what number 
of patients would be likely to give meaningful results.                                                                                                     
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SUMMARY
Inflammatory stimuli such as infection or tissue injury will produce a local 
inflammatory response which may, if the inflammatory response is sufficiently large, 
spill over to produce a systemic inflammatory response.  This is clinically 
characterized by a response in heart and respiratory rate, a temperature rise or fall and 
a white cell response.  Where the systemic inflammatory response syndrome is due to 
proven infection this is classified as sepsis.  If the inflammatory stimulus is removed 
or dealt with by the body or with medical treatment, the systemic inflammatory 
response may resolve with a return to homeostasis.  In some patients the response 
does not resolve and they may progress to an anti-inflammatory state which 
predisposes to infection and poor wound healing or progress to multi-organ 
dysfunction syndrome, often resulting in cardiac, respiratory or renal failure.  There is 
no specific treatment for multi-organ dysfunction syndrome and the practice of 
intensive care medicine has developed to support organ function in this period while 
the source of the illness is treated and the patient allowed time to recover.  Mortality 
remains high in intensive care medicine with in hospital mortality around 30-40%.
Clinically markers of systemic inflammation are used to assess improvement or 
deterioration in condition.  White cell count will be elevated in infection and is not a 
good indicator of systemic inflammation.  The pro-inflammatory cytokines such as 
IL-6 mediate inflammation.  These are secreted by activated macrophages of which 
80% are resident in the liver as Kupffer cells.  Cytokines act on the liver hepatocytes 
causing them to produce proteins.  Plasma proteins that change in concentration with 
inflammation are named acute-phase proteins and the most clinically important of                                                                                                      
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these is C-Reactive Protein.  It is usually found in the plasma at concentrations of 
3mg/l or less and values of less than 10mg/l are regarded as clinically unimportant.  
C-reactive protein is stable in plasma, does not increase with age, has little or no 
diurnal variation, changes rapidly with disease and has a wide range of abnormal 
values.  
The liver is a source of cytokines, a target for cytokines, manufactures proteins and is 
the site of gluconeogenesis in systemic inflammation and thus plays a pivotal role in 
the process.  In humans liver failure is rare in multi-organ dysfunction syndrome; 
however liver dysfunction is associated with poorer outcome in critical illness.  As the 
liver is hypermetabolic the delivery of blood would appear to be important in critical 
illness.
Liver blood flow has been studied in systemic inflammation but the relative 
inaccessibility of the portal vein and the hepatic artery has made this a difficult task.  
The few studies that have been performed in critically ill patients have used the Fick 
principal to allow estimation of total liver blood flow by clearance of a marker in the 
blood by the liver.  A requirement of this technique is hepatic venous catheterisation 
which is invasive and not without complications.  Advances in ultrasound technology 
have allowed colour Doppler/ duplex scanning of the hepatic artery and portal vein 
trans-abdominally and allow non-invasive measurement of not only total liver blood 
flow but also its individual components.  This technique has been shown to be reliable 
and reproducible and the results reported in Chapter 2 confirm with this in the 
authors’ hands.                                                                                                     
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The consensus from previous work is that total liver blood flow is increased in 
systemic inflammation.  As mentioned above the relative contributions of the hepatic 
artery and portal vein in these changes has not been studied.  In Chapter 3 a cross 
sectional study was performed in three different groups; controls, non-small cell lung 
cancers and acute alcoholic hepatitis.  These three groups were shown to be different 
in levels of systemic inflammation with the controls least and the hepatitics most 
inflamed.  Total liver blood flow was not significantly altered in these inflammatory 
disease states, nor was portal venous blood flow.  In contrast, there was a significant 
increase in hepatic arterial blood flow which was related to increased systemic 
inflammation.  The mediators of the increased hepatic arterial flow was not clear but it 
could be a hormonally mediated response, a cytokine mediated response or simply an 
intrinsic response to the increased metabolic demand that on the liver by systemic 
inflammation.
Previous liver blood flow studies in acute inflammation have been performed when 
inflammation is established and therefore it is difficult to define the chronological 
changes in liver blood flow.  A previous study utilised ultrasound to measure the liver 
blood flow at 5 and 24 hours after onset of inflammation.  This study reported an 
increase in hepatic arterial and portal venous blood flow at 5 hours compared to 
controls but no significant changes at 24 hours.  Studies with infusions of interleukin-
6 demonstrated an increase in liver blood flow that peaked at four hours in healthy 
volunteers.  We therefore hypothesised that there were changes in hepatic arterial and 
portal venous blood flow within the first 6 hours of an inflammatory stimulus.  In 
Chapter 4 serial hepatic arterial and portal venous blood flow measurements were 
made following the surgical trauma of lower limb arthroplasty.  An immediate fall in                                                                                                      
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portal venous flow was seen which was followed by an increase in hepatic arterial 
blood flow over the next four hours.  By 24 hours the hepatic arterial blood flow was 
not significantly different to the pre-operative value and the portal venous flow was 
returning to normal, although remained statistically lower than pre-operatively.
The immediate fall in portal venous flow is likely to be hormonally mediated, as we 
know the adrenal medullary hormones that are released in response to tissue injury or 
trauma, will direct blood away from the gut to selectively perfuse the brain, heart, 
lungs, kidneys and muscle.  The immediate effect would also favour a hormonal 
rather than a cytokine response.  The liver will immediately have a metabolic stress 
placed on it as it as gluconeogenesis is stimulated in hepatocytes.  After a period of 
time following tissue injury the Kupffer cells of the liver will begin to transcript for 
cytokines and the liver hepatocytes will be stimulated by these cytokines to 
manufacture acute phase proteins.  Whether the late increase in hepatic arterial flow is 
a direct effect from cytokines or a reactive response to increased metabolic rate in the 
liver is not readily addressed by this study.
Finally, we wished to assess changes in blood flow in the intensive care setting.  It has 
previously been reported that total liver blood flow is increased in critical illness 
compared to controls.  Studies over time have suggested that initially there is an 
increase in total liver blood flow compared to controls; however no significant change 
after 24 hours.  In Chapter 5 hepatic arterial and portal venous blood flows were 
measured in intensive care patients during their ITU admission.  There was no 
correlation between blood flows and level of systemic inflammatory response as 
assessed by C-reactive protein. A greater variability in blood flow measurements was                                                                                                      
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seen in non-survivors. The absence of drop in portal flow may be explained by 
aggressive fluid resuscitation in the first 24 hours of the ITU stay.  The absence of an 
increase in hepatic or total liver blood flow was not clear.
The present thesis identified changes in hepatic arterial and portal venous blood flow 
between groups of patients and following an inflammatory stimulus. Future work 
requires to examine which hormones and cytokines modify liver blood flow. This may 
be assessed by repeating the study in Chapter 4, where liver blood flow was measured 
following surgery, and by sampling blood for hormonal and cytokine analysis.  If the 
intrinsic control of the liver is responsible for these changes it would be important to 
show that the liver is more metabolic as the changes occur.  An intervention to lower 
the metabolic demand on the liver is difficult and may not be ethical given that the 
normal response to injury or infection is an acute phase response.  One area where this 
could be said to have been performed is the tight control of blood glucose in intensive 
care medicine which reduces the demand on the liver to perform gluconeogenesis.  
While there are other benefits of lower serum glucose levels this may contribute to the 
reported improved outcome in such patients.
Clinically, measurement of hepatic arterial and portal venous blood flow has been 
shown to be feasible in the critically ill patient and may be used as a non-invasive 
measurement of the liver response to a drug or therapy.
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Chapter 1:  Introduction                                                                                                     
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1.1     Response to injury
The four classical signs of local inflammation are rubor (redness), calor (heat), dolor 
(pain) and turgor (swelling).  These signs appear whether one has a cut to the skin, a 
burn to skin or boil under the skin and can be readily understood as a local response 
which increases the blood supply to the affected area and increases capillary 
permeability thus delivering the appropriate blood cells to fight infection or building 
blocks to repair tissue, while providing an environment hostile to bacteria and moist 
to prevent drying out of damaged tissues.
This local response also produces proteins that act as signals to other cells locally.  
These proteins have been classed as cytokines/ chemokines and act on blood vessels 
to increase their diameter and permeability to plasma proteins.  If this cytokine/ 
chemokine response is sufficiently large it stimulates a systemic response in other 
organs distal to the injury which has been termed the acute phase response or more 
correctly the systemic inflammatory response (1). 
Even in the 18
th century the concept of a total body response to local injury was 
beginning to be recognised.  The earliest observation of this was by John Hunter(2) in 
1794 who stated in his publication, “Treaties on the blood, inflammation and gunshot 
wounds” that “There is a circumstance attending accidental injury which does not 
belong to disease, namely, that the injury done, has a tendency to produce both the 
disposition and the cure.”  In 1852 Cole (3) made the observation,  “The arteries 
contract and retract to the saving of many a life….  Whether haemorrhage will or will 
not follow a gunshot wound mainly depends on the amount of physical prostration                                                                                                      
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and collapse produced by the violent shock to the system.”  Malcolm (4) described a 
systemic response to injury in 1893, telling us “shock is more a part of the phenomena 
caused by injury, surgical or otherwise, than a complication thereof.”  He termed the 
systemic response of pyrexia ‘Traumatic Fever’.
Cuthbertson developed this concept of a systemic multi-organ response rather than 
only a local tissue response to injury.  He describes two phases of response.  Initially a 
short ‘ebb phase’ or ‘wound shock,’ lasting a few hours, during which there is relative 
or absolute anuria, decreased heat production and body temperature and decreased 
nitrogen excretion.  A flow phase, lasting a few days was then described during which 
there is a marked urinary loss of nitrogen, sulphur and phosphorous, increased heat 
production and increased body temperature.  The urinary losses were such that they 
could not be part of a local tissue response alone and he concluded that the healing 
process required breakdown of protein mass from other tissues in particular skeletal 
muscle (5).
Subsequently, this flow phase response injury was found to result in increased plasma 
levels of amino acids, derived from skeletal muscle tissue; and increased liver 
gluconeogenesis from amino acids (6).  The consequent hyperglycaemia was found to 
be resistant to the supplementation of insulin (7) and there were increased plasma 
concentrations of the counter regulatory hormones; cortisol, glucagon, and adrenaline.  
Indeed, when these three hormones were infused separately there were transient 
increases in hepatic glucose production.  Furthermore when they were infused 
together this lead to a prolonged elevation of glucose production and a synergistic 
response was evident (8).                                                                                                     
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It is also of interest that there were increases in cardiac output and changes in organ 
blood flow both following significant injury (9) and after glucagons (10) or adrenaline 
(11) infusion.  Levels of the triple hormones equivalent to the infusion studies were 
found to be associated with increases in blood flow.   In particular there was an 
increase in splanchnic blood flow whereas renal blood flow was unaltered (9).  One 
explanation is that the liver being central to substrate metabolism requires increased 
delivery of oxygen, nutrients and substrates and thus requires increased blood flow.  
These workers were not able to distinguish the blood flow to the liver from the other 
components of splanchnic blood flow.  Animal studies have not appeared to be useful 
in this regard since, following an inflammatory stimulus, there appears to be a 
decrease in blood flow inconsistent with human studies (12-14).
The effect of the triple hormone infusion on acute phase protein production and 
nitrogen balance was not as profound as that seen in equivalent injury (15;16).  This 
indicated that some other messenger or messengers was involved in the systemic 
inflammatory process (16).  In the last decade or so there has been a great deal of 
interest in the role of cytokines/ chemokines/ leukotrienes in the systemic 
inflammatory response.  This originates from work on a heat labile protein from 
activated leukocytes that caused a systemic fever when injected peripherally (17).  
This substance was variously termed granulocytic, leukocytic or endogenous pyrogen 
(EP).  Until 1974 it was assumed that EP was a single molecule, however Dinarello 
and co-workers (18) characterized two distinct molecules derived from human 
monocytes and for the remainder of this decade a number of molecules with similar 
properties and different chemical characteristics were being identified (19).  It became                                                                                                      
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apparent that EP was the same molecule as lymphocyte-activating factor which was 
subsequently termed as interleukin-1.  IL-1 had previously been studied as leukocyte 
endogenous mediator and was found to increase synthesis of acute phase liver
proteins and liver RNA (20).  As well as fever and acute phase protein induction, IL-1 
appeared to cause the release of amino acids from muscle in vitro (21;22), as similarly 
seen in patients with elevated cortisol, glucagon and adrenaline levels.
IL-1 was the first molecule to be endogenously purified and characterized as both a 
pyrogenic and lymphocyte-activating molecule; however two other molecules shared 
these characteristics and could also induce acute phase protein production.  These 
were interleukin-6 (IL-6) and tumor necrosis factor (TNF).  TNF is a macrophage 
product so named as it has a direct cytotoxic effect on certain tumour cells.  It shares 
many biological properties with IL-1, however their amino acid sequences differ 
significantly (23).  Consistent with this framework, following the stress hormonal 
response, TNF is the first cytokine to be found in elevated concentrations in the 
plasma, around two hours following injury (24) as it is continually transcribed by 
macrophages (25).   IL-1 is the next cytokine that appears and this is followed by IL-
6.  IL-6 appears later as its gene expression must be induced.  This expression is 
enhanced by the presence of IL-1 but especially by IL-1 plus TNF (26).
Release of these pro-inflammatory cytokines also stimulates release of anti-
inflammatory cytokines (e.g. IL-4 and IL-10) and cytokine soluble receptors to bind 
to the pro-inflammatory cytokines.  As combinations of cytokines act on target cells 
and may as a result have an additive, inhibitory or synergistic effect (27).                                                                                                     
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Systemic inflammation occurs where there is a loss of control of the local 
inflammatory response and there is a systemic spill over of pro-inflammatory 
cytokines (28).  This response is thought to enhance the recruitment of blood products 
to the site of inflammatory stimulus.  If the stimulus is then blocked or resolved, anti-
inflammatory cytokines, hormones and other factors return the body to homeostasis.  
If the inflammatory stimulus continues we see loss of regulation of the inflammatory 
response and a systemic inflammatory response syndrome.  Several genetic factors 
which make the progression of systemic inflammation to multiple organ dysfunction 
syndrome more likely, have been identified and certain individuals may be 
predisposed to increased severity of illness (29;30) as their expression of pro- and 
anti- inflammatory agents is altered.
Clinically, causes of a systemic inflammatory response syndrome that we see in the 
intensive care setting include infection, trauma (including surgery), burns, tissue 
infarction and pancreatitis.  The development of this response can be thought of as a 
‘kill or cure’, allowing the body to fight infection/ heal itself or die trying.  With 
developments in intensive care medicine over the last 50 years, we can support a 
number of organs while treating the stimulus to the inflammation.  Therefore, a 
continuing systemic inflammatory response may well be detrimental to the outcome 
overall.                                                                                                     
24
1.2 Aetiology, clinical course and treatment of the systemic inflammatory 
response in the critically-ill patient
The systemic inflammatory response syndrome describes a spectrum of stereotypical 
changes in host metabolism which vary in magnitude and duration.  This ranges from 
individuals who resolve their inflammatory response without intervention to cases in 
which modest intervention such as antibiotics or elective surgical intervention will be 
required and to those patients who will require specialist care in a critical care setting.
Those patients with significant disturbance of their body homeostasis require 
definition of pathologies and grading of the different levels of response to the injury 
or insult.  Definitions of critical illness and scoring systems to describe severity of 
illness have been developed to attempt to overcome this problem.
Until 1992 there were many terms being used without clear definitions for the same 
phenomenon that was seen in these patients.  The presence of an inflammatory 
stimulus, the physiological response of tachycardia, tachypnoea, pyrexia and white 
blood cell response, the progression onto hypotension and the further progression into 
multi-organ failure were variously named sepsis, severe sepsis, shock, multi-organ 
failure or systemic inflammation.  These terms were not specific and therefore 
potentially confusing.  In 1991 the members of the American College of Chest 
Physicians and the Society of Critical Care Medicine held a consensus conference 
(31) and decided on the following standardised definitions.                                                                                                     
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 Systemic Inflammatory Response Syndrome (SIRS)
A response to an inflammatory stimuli resulting in two or more of the following 
clinical manifestations:
a) a body temperature of >38C or <36C
b) a heart rate of >90 bpm
c) tachypnoea, a respiratory rate of >20 or hyperventilation, PaCO2 <4.3kPa
d) an alteration of WCC of >12,000 cells/mm
3, or <4000cells/mm
3, or the 
presence of >10% immature neutrophils.
 Sepsis
The presence of Systemic Inflammatory Response Syndrome as the result of a proven 
infectious process.
 Severe Sepsis
Sepsis associated with organ dysfunction, hypoperfusion or hypotension (systolic 
blood pressure <90mmHg or reduction of 40mmHg or more, from baseline).  
Hypoperfusion and perfusion abnormalities may include lactic acidosis, oliguria or an 
acute alteration in mental status.
 Septic Shock
Sepsis with hypotension, despite adequate fluid resuscitation, along with the presence 
of perfusion abnormalities.  Blood pressure may be normal in the presence of 
inotropic support but a patient is still considered to have septic shock if hypoperfusion 
abnormalities are present at this time.                                                                                                     
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 Multiple Organ Dysfunction Syndrome
Presence of altered organ function in an acutely ill patient such that homeostasis 
cannot be maintained without intervention.
These definitions have enabled studies looking at prognostic values and 
therapeutic interventions in intensive care patients to be standardised.  Ten years after 
these definitions were introduced, a further consensus group of physicians working in 
critical care met to discuss if they could improve upon the original definitions (32).  
Their findings were that the 1992 guidelines required no modification other than to 
expand the list of signs and symptoms of sepsis.
1.2.1  Assessment of magnitude of inflammatory response by use of a severity score
Critical illness develops in a wide range of specialties and in this heterogeneous group 
it has always been difficult to compare outcomes and clinical management.  A scoring 
system of illness severity is required for audit and comparison of intensive care units, 
which can also be used to predict outcome.  For this purpose the APACHE II (acute 
physiological and chronic health evaluation) scoring system (33) is most commonly 
used.  APACHE II derives an acute physiological score in the first 24 hours of 
admission from 12 basic physiological indices including temperature, cardiovascular 
and respiratory status as well as biochemical and haematological variables.  This is 
added to a chronic health evaluation.  The admission diagnosis is then used to 
calculate a predicted mortality for an individual.  Predicted mortality is compared to                                                                                                      
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actual mortality in a cohort of patients and a standardised mortality ratio for a unit can 
be calculated.  This allows assessment of the therapeutic efficacy of a unit.
However, APACHE II should not be used to decide on which patients should be 
admitted to intensive care.  This was highlighted in a document produced by a 
working group on admission to and discharge from intensive care and high 
dependency (DoH, 1996) and they conclude that APACHE II is a “probabilistic and 
not predictive” scoring system. 
1.2.2  Clinical course of SIRS/Sepsis
Inflammatory stimuli can lead to a spectrum of outcome and it is not fully understood 
why two patients with equivalent injuries can have very different outcomes; one may 
have very little in the way of systemic upset and recover fully, the other may quickly 
progress to multiple organ dysfunction syndrome and death.  We can group patients 
into one of four categories to describe their clinical course (34).
1. Little evidence of systemic reaction, organ dysfunction rarely 
develops.
2. Mild systemic inflammatory response syndrome and some 
evidence of organ dysfunction early in clinical course of 
disease.  Dysfunction usually limited to one or two organs and 
rapidly resolves.                                                                                                     
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3. Massive systemic inflammatory reaction rapidly develops after 
initial insult.  Often leads to death from profound shock within 
one or two days.
4. Less severe initial course but marked deterioration several days 
after initial insult.  Multiple organ failure is common and many 
patients die.
Until the mid 1990s it was felt that pro-inflammatory molecules were the only 
substances mediating the progression of systemic inflammation to multiple organ 
dysfunction.  Trials to reduce mortality in sepsis were attempted using anti-
inflammatory agents and soluble receptors to bind the pro-inflammatory cytokines, 
however this did not improve mortality and may even have been harmful (35).  The 
systemic anti-inflammatory response was clearly just as important as the pro-
inflammatory response and Bone described how a pro- or anti-inflammatory 
predominance would manifest clinically.  He described the inflammatory response at 
various stages of multiple organ failure (36).
Stage 1
Injury or insult induces the pro-inflammatory response locally.  These mediators act to 
destroy damaged tissue, promote growth of new tissue and combat pathogens, 
antigens or neoplastic tissue.  The compensatory anti-inflammatory response (CARS) 
is triggered to ensure the pro-inflammatory mediators do not become destructive and 
limits pro-inflammatory cytokine production.  This is a local response and no 
systemic clinical signs or symptoms are seen.                                                                                                     
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Stage 2
If the injury is sufficient, pro-inflammatory and then anti-inflammatory mediators 
appear in the systemic circulation.  Pro-inflammatory mediators recruit neutrophils, T 
and B cells, platelets and coagulation factors to the site of tissue injury.  This cascade 
stimulates a compensatory anti-inflammatory response that counters the pro-
inflammatory state.  It is unusual to see clinical signs or symptoms and organ 
dysfunction is rare.
Stage 3
If regulation of the pro-inflammatory response is lost, the systemic response manifests 
as the clinical findings of Systemic Inflammatory Response Syndrome.  We see 
increased systemic vascular permeability, platelet sludging, coagulation cascade 
activation and systemic vasodilatation.  Organ dysfunction and failure may result 
unless homeostasis can be quickly restored.  Clinically we see changes in the 
parameters that define a systemic inflammatory response syndrome; elevated or low 
white cell count, high or low temperature, tachycardia and increased respiratory rate.
Stage 4
Compensatory anti-inflammatory response can predominate causing 
immunodeficiency.  This has been described as “immune paralysis” or “window of 
immunodeficiency”.  Monocytes have a diminished ability to produce pro-
inflammatory cytokines(37) and overwhelming infection is seen.
Stage 5
The last stage of multiple organ failure syndrome is where the body is secreting 
inappropriately large amounts of pro- and anti-inflammatory mediators and 
monocytes are deactivated.  This has been called “immunological dissonance” by 
Bone.  At this stage multiple organs require support and death is the likely outcome.                                                                                                     
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The predominant systemic response manifests clinically in one of 5 ways as described 
in Figure 1.1.  The term MARS describes the mixed antagonists response syndrome 
where there are features of SIRS in patients with CARS.  While treating intensive care 
patients with multi-organ dysfunction syndrome we are, in essence, supporting organ 
function while the immune system attempts to restore homeostasis.  
1.2.3  Management of systemic inflammation
While many patients will resolve the inflammatory process without clinical assistance, 
intervention in the form of surgery or antibiotic therapy may be required.  If the 
stimulus can be corrected surgically and the patient is fit enough, this should be 
undertaken.   Drainage of abscesses can also be performed radiologically if general 
anaesthesia presents too much of a risk.  Antibiotics can be administered, either as 
broad-spectrum cover or specific to pathogen once culture and sensitivity are known.  
While the patient recovers from this and until immunological homeostasis is returned, 
organ support may be necessary.
Two documents currently provide guidelines and standards for intensive care in the 
UK.  “Guidelines on admission and discharge from intensive care and high 
dependency units” published by the Department of Health in 1996 and “Standards for 
intensive care units” by the Intensive Care Society inform us which patients are 
appropriate for intensive care:                                                                                                     
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 Patients requiring or likely to require advanced respiratory support alone (e.g. 
intermittent positive pressure ventilation).
 Patients requiring support of two or more organ systems.
 Patients with chronic impairment of one or more systems sufficient to restrict 
daily activities (co-morbidity) and who require support for an acute reversible 
failure of another organ system.
Categories of organ system monitoring and support are defined thus:
1. Advanced Respiratory Support
 Mechanical ventilatory support excluding mask continuous positive 
airways pressure (CPAP) or non-invasive (e.g. mask) ventilation.
 Possibility of a sudden, precipitous deterioration in respiratory function 
requiring immediate tracheal intubation and mechanical ventilation.
2. Basic Respiratory Monitoring and Support
 The need for more than 40% oxygen via fixed performance mask.
 The possibility of progressive deterioration to the point of needing 
advanced respiratory support (see above).
 The need for physiotherapy to clear secretions at least two-hourly, 
whether via a tracheostomy, a mini-tracheostomy, or in the absence of 
an artificial airway.
 Patients recently extubated after a prolonged period of intubation and 
mechanical ventilation.
 Patients who are intubated to protect the airway, but needing no 
ventilatory support and who are otherwise stable.                                                                                                     
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3. Circulatory Support
 Need for vasoactive drugs to support arterial pressure or cardiac 
output.
 Support for circulatory instability due to hypovolaemia from any cause 
and which is unresponsive to modest volume replacement. This will 
include, but not be limited to, post-surgical or gastrointestinal 
haemorrhage or haemorrhage related to a coagulopathy.
 Patients resuscitated following cardiac arrest where intensive or high 
dependency care is considered appropriate.
4. Neurological Monitoring and Support
 Central nervous system depression, from whatever cause, sufficient to 
prejudice the airway and protective reflexes.
 Invasive neurological monitoring.
5. Renal Support
 The need for acute renal replacement therapy (haemodialysis, 
haemofiltration, or haemodiafiltration).
All aspects of intensive care medicine have been developed in recent years but there 
are a few interventions deserving of special mention that have changed intensive care 
practice and reduced mortality.  
 Avoiding hypothermia by means of space blankets, forced air warming 
devices and blood warmers had been shown to decrease the 
complications of poor wound healing, exaggerated inflammatory 
response, ischaemic myocardial events and coagulopathy (38;39).                                                                                                         
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 Ventilator induced barotrauma has been reduced by enhancing alveolar 
recruitment and avoiding alveolar overdistention by lowering tidal 
volumes and the use of positive end expiratory pressure during 
ventilation (40).
 Physiological doses of hydrocortisone have been found to decrease 
mortality in patients with septic shock and it is patients with adrenal 
insufficiency who gain the most benefit (41).  
 Insulin intolerance has been described for many years but it is only 
recently that tight control of glucose levels in all patients with sepsis 
has been demonstrated to decrease the incidence of septic 
complications and mortality (42).
As discussed above, trials where there has been administration of an anti-
inflammatory agent in sepsis have not been successful as the systemic inflammatory 
response is not just a pro-inflammatory response.  While trials of anti TNF (43) and 
IL-1 (44) have not shown any benefit, synthetic activated protein C appears to reduce 
mortality from sepsis in a subset of patients (45).  Activated protein C is an 
endogenous protein that promotes fibrinolysis, inhibits thrombosis and inhibits 
inflammation.  A large randomized controlled trial showed that activated protein C 
lowered IL-6 concentrations in the treatment arm and reduced mortality.  
Recombinant activated protein C is now used in everyday use in ITU to treat patients 
with severe sepsis and is recommended in current NICE guidelines {NICE TA84}.  
Recently the incidence of bleeding has been reported as higher than initially thought 
and the treatment itself may not be as effective as initially reported (46).  Research 
into finding effective agents in sepsis continues.                                                                                                     
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Figure 1.1 
Clinical sequelae of sepsis
From Bone RC.  Sir Isaac Newton, sepsis, SIRS, and CARS.  Critical Care Medicine 1996; 
24:1125-28
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1.3 The role of the liver in the development of a systemic inflammatory 
response
When tissue injury or septic foci are significantly severe there is activation of the 
Kupffer cells in the liver.  Approximately 80% of the total body macrophages are 
resident in the liver (47) as Kupffer Cells.  When radiolabelled E. Coli was injected 
intravenously into rats, 80% of the bacteria were found in the liver 5 minutes after 
injection (48).  The Kupffer cells produce pro-inflammatory mediators, such as TNF-
alpha, interleukin-1 and interleukin-6, when activated by lipopolysacccharide (LPS) 
(49-53) or by tissue injury(54).  In infection the Kupffer cells mop up the bacteria 
components released by lysis mediated by cellular defence mechanisms.  The Kupffer 
cells are activated when they recognise the attached complement and IgG with the 
bacterial components (55), while the pathway to activation of macrophages in tissue 
injury is not fully understood.  The activated macrophage becomes hypermetabolic 
and increases its intracellular store of oxygen free radicals and other microbicidal 
agents as well as secreting inflammatory mediators(56;57).
Following significant tissue injury or sepsis the first pro-inflammatory mediator to be 
detected in the systemic circulation is tumour necrosis factor alpha (TNF-).  This 
cytokine is continually transcribed by Kupffer cells and allows for immediate release 
after inflammatory stimulus (25). TNF- is found in serum within an hour of 
endotoxin infusion in human volunteers (54).  This is followed by the appearance of 
interleukin-1 at around on hour post injury.  Although IL-1 is found in high 
concentrations at the site of inflammatory stimulus, increased circulating 
concentrations are uncommon (24).  At two hours after endotoxin administration a                                                                                                      
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peak in the serum levels of interleukin-6 (IL-6) is seen (54).  Unlike TNF-, IL-6 is 
not continuously expressed.  An inflammatory stimulus results in the immediate 
transcription of mRNA for IL-6 in liver macrophages, and this accounts for the lag.   
This has been demonstrated in mice, where IL-6 mRNA levels are at their maximum 
following stimulation of the liver macrophages (25;58).  These experiments were 
performed in animals or healthy volunteers given an infusion of endotoxin and 
probably do not give a true approximation of the timings of peaks of these cytokines 
in the clinical setting of tissue injury or infection.  Measurement of cytokines in the 
post-operative setting shows TNF levels unchanged following uncomplicated surgery 
and a peak in systemic IL-6 at around 24 hours (59).  During these initial events 
following infection or injury, the blood flow to the liver is increased out of proportion 
to blood flow to other visceral organs(9).
1.4  The role of the liver in propagation of the systemic inflammatory response
The predominant effect in the liver of pro-inflammatory mediators is the induction of 
hepatocytes to produce acute phase proteins (1).  IL-6 is the most important as it 
orchestrates synthesis of the acute phase proteins (60), although receptors for most 
pro-inflammatory agents can be found on the surface of hepatocytes.  Increased 
production of the acute phase proteins by hepatocytes can lead to an increase in serum 
levels by a factor of 1000(61).
The acute phase proteins (APP) are proteins that demonstrate a change in plasma 
concentration of at least 25% in response to an inflammatory stimulus.  These proteins 
can show an increase in concentration (positive APP) or a decrease (negative APP).                                                                                                       
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Changes in plasma concentrations are due to increases or decreases in synthesis by 
hepatocytes, induced by IL-6 and an appropriate hormonal environment.   In 
particular IL-6 is known to stimulate production of C-reactive protein.  C-Reactive 
Protein appears to be made of 5 identical non-covalently bound subunits (62).  The 
function of C-reactive protein in inflammation is complex and its major function is to 
bind phosphocholine and activate the complement system (63).  It also induces the 
pro-inflammatory cytokines and tissue factor in monocytes (64).  C-reactive protein 
starts to increase its systemic circulating concentration at 12 hours post injury and 
peaks at 48 hours in the absence of ongoing infection/injury(65;66).
C-reactive protein is the most widely used marker of the inflammatory response and 
has various properties that make it useful.  It is usually found in the plasma at 
concentrations of 3mg per litre or less and values of less than 10mg per litre are 
regarded as clinically unimportant(67).  C-reactive protein is stable in plasma (68), 
does not increase with age, has little or no diurnal variation (69), changes rapidly with 
disease and has a wide range of abnormal values (1).  Elevated concentrations of C-
Reactive Protein have been found to be an indicator of poor prognosis in malignant 
(70;71) and inflammatory conditions such as pancreatitis(72).  Elevated 
concentrations of C-Reactive Protein are correlated with poor survival in a variety of 
common solid tumours and particularly in advanced disease (73).  Its value in 
predicting severity of pancreatitis is limited by the physiological property described 
above, in that it does not peak until 48 hours post insult.  C-Reactive Protein at 48 
hours is a good indicator of severity of pancreatitis (74).  This has not altered clinical 
practice as better prognostic indicators are available (75).                                                                                                     
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1.5  The role of the liver in resolution of the systemic inflammatory response
We have discussed the pro-inflammatory effects of C-reactive protein but its 
predominant effect may be anti-inflammatory.  C-reactive protein prevents adhesion 
of neutrophils to endothelial cells and inhibits the generation of superoxides by 
neutrophils, inducing synthesis of IL-1-receptor antagonist (76).  Other acute phase 
proteins also have anti-inflammatory effects either by protecting against reactive 
oxygen species (haptoglobin and hemopexin), antagonizing proteolytic enzymes (α1-
protease inhibitor and α1-antichymotrypsin), or preventing generation of superoxide 
anion (α1-antichymotrypsin) (1;77).  Two positive acute phase liver proteins are also 
important in tissue healing; fibrinogen causes endothelial cell adhesion, spreading and 
proliferation and haptoglobin stimulates angiogenesis (78).
In summary, metabolic activity in the liver is increased in injury and sepsis; Kupffer 
cells secrete inflammatory mediators, hepatocytes synthesize acute phase proteins and 
increase gluconeogenesis from muscle amino acids.  To compensate for this the 
oxygen extraction fraction of the liver is increased (79).  The liver plays a pivotal role 
in the maintenance of homeostasis and liver blood flow is key to this role.
1.6  Role of the liver in critically ill patients
In humans, the liver is a key organ in the development, propagation and resolution of 
systemic inflammation and appears to be relatively protected from failure during multi 
organ dysfunction syndrome. In humans, liver dysfunction is more common than                                                                                                      
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failure, however liver dysfunction is associated with an increased mortality in the 
critically ill patient (80-85).  Liver dysfunction is usually evidenced by elevated 
circulating concentrations of bilirubin, transaminases or a prolonged prothrombin time 
(Tables 1.2 and 1.3).                                                                                                     
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Table 1.2
Studies Patients Criteria
Fry et al
Tran et al
Hebert et al
Fagon et al
Bakker et al
Perl et al
553 postop patients
487 ICU patients
250 septic patients
1070 ICU patients
81 septic patients
103 septic patients
Bilirubin >34 and AST and LDH >twice normal values
Clinical jaundice or bilirubin >51 in the absence of hemolysis; 
ALT > twice normal values; hepatic encephalopathy
Bilirubin >60 or alk phos >350U/L
One or more of the following: bilirubin >100; alk phos >3 times 
normal
Bilirubin >34 without hemolysis and AST and ALT >80U/L
Bilirubin >34 and alk phos, GGT, AST or ALT > twice upper 
limit of normal in absence of pre-existing disease
Bilirubin= micromols/litre
From Pastor CM et al.(47)
References:
Fry et al(83), Tran et al(86), Hebert et al(82), Fagon et al(81), Bakker et al(87), Perl et al(88)                                                                                                     
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Table 1.3
Severity Grading Score
Studies Patients 0 1 2 3 4
Goris et al 92 ICU 
patients
AST <25 and 
Bilirubin <34
AST 25-50 or 
bilirubin 34-
103
AST >50 or 
bilirubin >103
Carrico et al Chemical 
jaundice
Clinical 
jaundice
Encephalopathy
Deitch et al Bilirubin 34-51 
or LFT twice 
normal values 
(dysfunction)
Clinical 
jaundice with 
bilirubin >137 
(advanced 
failure)
Smail et al 163 trauma 
patients
Bilirubin >34 Bilirubin 68-
137, PT >2s 
over control
Bilirubin <137, 
PT>4s over 
control
Marshall et al Medline 
database
Bilirubin<20 Bilirubin 21-60 Bilirubin 61-
120
Bilirubin 121-
240
Bilirubin >240
Le Gall et al ENAS 
database
Bilirubin <34 
and PT <3s 
over control
Bilirubin 34-68 
and PT >3s 
over control
Bilirubin >68
Vincent et al 1449 ICU 
patients
Bilirubin <20 Bilirubin 21-32 Bilirubin 33-
101
Bilirubin 102-
204
Bilirubin >204
Stevens et al 30 septic 
patients
Increased LDH 
and AST, 
normal 
bilirubin
Bilirubin 21-43 Bilirubin 44-82 Bilirubin 83-
137
Bilirubin >137
Bilirubin micromols/litre, others units/litre
From Pastor CM et al(47)
Reference:  Goris et al(85), Carrico et al(89), Deitch et al(90), Smail et al(91), Marshall et al(92), Le 
Gall et al(84), Vincent et al(93), Stevens et al(94).                                                                                                     
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1.7 Liver Blood Flow
1.7.1  Liver Blood Flow in Health
Anatomy
The liver receives around a quarter of the total cardiac output and this is supplied in 
two ways.  Around a third of the total liver blood flow is arterial blood from the 
common hepatic artery.  The remainder of the liver blood supply is received via the 
portal vein.  This is made up from the superior mesenteric and splenic vein with a 
small contribution from the venous drainage of the pancreas and omentum.  The 
inferior mesenteric vein usually joins the splenic vein before it joins the superior 
mesenteric vein to form the portal vein.
Histologically, these vessels main convergence is at the inlets to the hepatic sinusoids 
where the arterial and portal venous blood mix.  In humans, a sphincter of vascular 
smooth muscle controls these inlets (95;96).  Convergence is also found to a lesser 
degree before the sinusoids.  Direct arterioportal anastomosis and peri-biliary 
capillary networks can be demonstrated (95;97).
Physiology
The liver receives 25% of the cardiac output in the resting state and between a third 
and a fifth of this is from the hepatic artery.  Hepatic arterial blood flow and portal 
venous blood flow interact closely.  A change in flow through one of the circuits 
causes the opposite change in the other circuit (98).  The mechanism for this is not 
clear and is likely to be regulated by the pre-hepatic connections described above, 
however its effect is to maintain a constant liver blood flow.                                                                                                     
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Oxygen extraction is 20-35% of total body oxygen consumption and the liver has a 
higher oxygen extraction ratio when compared to systemic oxygen extraction (14).  
During exercise the blood flow to the muscles is increased at the expense of the gut 
and liver.  The liver responds to this by increasing its oxygen extraction (79).  
Hypoxia superimposed on exercise can increase the oxygen extraction up to 90% 
indicating the liver has a great capacity to increase oxygen extraction (99).
Blood flow to the liver can be regulated by modification of the hepatic arterial or 
portal venous flow.  Flow through the hepatic artery is proportional to arterial blood 
pressure and this relationship is approximately linear.  Portal venous flow is modified 
in many ways and this includes neurological control of the vascular smooth muscle, 
drug effect and hormonal effect, and are best discussed split into intrinsic and 
extrinsic factors (98).
Intrinsic control
The intrinsic factors modifying liver blood flow include local metabolic control and 
myogenic control, local reflexes and locally produced vasoactive substances.  This 
can occur in the liver, affecting mainly the hepatic arterial blood flow, or in the 
intestine, causing changes in the portal venous flow.
1) Metabolic control
When blood supply is not sufficient to meet the metabolic needs of a tissue, metabolic 
products such as hydrogen ion (100), adenosine, ATP, ADP, AMP(101) or an increase                                                                                                      
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in plasma osmolality (102) leads to local vasodilatation and an increase in blood flow.  
The same would appear to be happening in the gut and liver, although how this is 
mediated has not been identified.  
2) Myogenic control
The myogenic control responds to increased vascular transmural pressure (increased 
venous pressure) by constriction of the arteriolar smooth muscle.  This in turn 
increases vascular resistance and maintains a constant flow (100;103-105).  
Overall adequacy of perfusion will determine which of these two control mechanisms 
will predominate, if perfusion is adequate an increase in venous pressure will cause 
arteriolar vasoconstriction by the myogenic pathway.  If perfusion is poor, metabolic 
control will decrease vascular resistance and increase blood flow.
This autoregulation of splanchnic blood flow is not as tight as in other organs, for 
example the kidney where a drop in arterial pressure will result in decreased 
resistance in this organ such that constant blood flow is maintained.  In the gut, blood 
flow will decrease if arterial pressure drops, despite vasodilatation, although 
autoregulation is better in the fed state than the fasting state (106;107).
Extrinsic control
After a meal we have an increased total liver blood flow and the mechanism for this 
would appear to be an increase in portal osmolality (102;108).  Increased systemic 
osmolality (which occurs postprandially) reduces the vascular resistance in the small 
intestine and hepatic vascular beds, increasing blood flow in the portal vein and                                                                                                      
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hepatic artery respectively(11;108;109).  Cholecystokinin is also suggested to play a 
role in the postprandial increase in total liver blood flow (11).
The sympathetic nervous system is the most important neural regulatory mechanism 
in the splanchnic blood flow.  Increased sympathetic nervous activity results in a 
decrease in gut blood flow (110;111), mainly by acting on the arteries and arterioles 
rather than the veins.  The aim of this reflex would be to divert blood from the gut to 
the heart, brain and muscles as part of the ‘fight or flight’ response.  This reflex is not 
prolonged and the flow to the gut and liver recovers despite continuing sympathetic 
stimulation (112), termed autoregulatory escape.  In the liver the action of the 
sympathetic nerves also causes a reduction in hepatic volume by stimulating the 
capacitance vessels to contract (113).  This occurs slowly and acts for the duration of 
sympathetic stimulation, not exhibiting autoregulatory escape.  The function of this 
mechanism would be, again, to allow redistribution of blood to other organs.
Of the many circulating hormones that affect liver blood flow, catecholamines are the 
most important.  Arterioles exhibit both alpha and beta adrenoceptors with opposite 
actions.  Alpha adrenoceptor stimulation results in vasoconstriction and beta 
adrenoceptor stimulation in vasodilatation (114).  Thus the effect of a bolus of 
circulating adrenaline induces the same ‘fight or flight’ decrease in liver and gut blood 
flow that is seen in sympathetic stimulation.  However, at lower circulating levels a 
vasodilatation is seen with adrenaline (11).  Experimentally vasopressin(115) and 
angiotensin(116) have been found to be potent vasoconstrictors in the splanchnic 
circulation but how this affects the normal physiological regulation of liver blood 
flow is not fully understood.  Glucagon also has a number of effects on gut and liver                                                                                                      
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vasculature, however its effects are only demonstrated at high concentrations such as 
those seen in sepsis and have been mentioned previously.  The role of glucagon in the 
healthy liver is not known.                                                                                                     
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1.7.2  Liver blood flow in SIRS/Sepsis
As we have discussed earlier, systemic changes following trauma were noticed many 
years ago.  These haemodynamics changes have been further studied and since the 
1960’s it has been accepted that cardiac output is raised in SIRS (117).  This was first 
studied using pulmonary artery catheters but more recently trans oesophageal echo-
Doppler (118) and peripheral lithium dilution (119) techniques have been used.  This 
increase in cardiac output appeared to correlate with increases in serum IL-6 
concentration (118).
Despite the many functions of the liver in systemic inflammation there have only been 
five studies where intensive care patients with SIRS were compared to controls 
(although one paper uses historical controls) or differing degrees of critical illness.  
Each paper shall be discussed and we shall also review additional literature that may 
help us to understand liver blood flow in systemic inflammation.                                                                                                     
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Aulick et al (9) assessed cardiac output, renal blood flow and splanchnic blood flow in 
13 non-infected burns patients and 5 control subjects.  Renal blood flow was 
estimated using clearance of para-aminohippurate and splanchnic flow by clearance of 
indocyanine green.  The study reported that the renal blood flow proportion of cardiac 
output was not increased in burns patients compared to controls.  An increase in 
splanchnic blood flow as a proportion of cardiac output was seen.  In controls 
Wilmore and colleagues (120) characterised changes in hepatic blood flow and 
metabolism in 31 burns patients.  These patients in the 1
st to 3
rd week post injury were 
classified as non-infected (8 studies), bacteraemic (8 studies) or bacteraemic with 
complications (5 studies).  Indocyanine green (ICG) was given as a bolus with hepatic 
vein and radial artery sampling post injection to determine cardiac output and hepatic 
clearance of ICG and thus estimate hepatic blood flow.  This study provided no 
information on hepatic arterial and portal venous flow.  Patients with burns injury 
alone had increased hepatic blood flow, hepatic oxygen uptake and gluconeogenesis.  
Infection on top of this increased hepatic glucose output and in patients with
bacteremia and complications glucose output fell.  This study reported, for the first 
time, that hepatic blood flow increased following burns injury.  The authors appear to 
have tried to differentiate between what we would now call SIRS, sepsis and MODS; 
and demonstrate that there were different changes in metabolism and haemodynamics 
of the liver for increasing severity of illness.  It was also important that this study 
showed that gluconeogenesis only occurred in the liver, post injury, by cannulation of
the renal vein in the same patients.                                                                                                     
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splanchnic blood flow accounted for 19% of the cardiac output while in burns patients 
this proportion rose to between 20 and 25%.  No details were provided on the control 
patients.  The authors suggested that this was a liver phenomenon as the changes were 
not simply a reflection of cardiac output as seen with the increased renal flow in 
burns.
When 7 injured patients were compared to 12 patients with sepsis and stable vital 
signs by Dahn et al (79), cardiac output was measured and total liver blood flow was 
estimated.  Studies were carried out at the same time of day to avoid any circadian 
influences.  Measurements in non-septic patients were compared to those in septic 
patients and while no significant difference was seen in total body oxygen 
consumption or splanchnic flow as a fraction of cardiac output, significant increases 
were found in splanchnic oxygen consumption, cardiac index and venous oxygen 
tension.  The authors felt that the most important finding of this study was that in 
septic patients, compared to non-septic patients, a significantly larger fraction of total 
body oxygen extraction was taken by the splanchnic circulation (44% vs. 30%).  This 
paper suggested that, as splanchnic blood flow was a relatively constant 25% of 
cardiac output, hepatic dysfunction seen in sepsis was due to hepatic ischaemia- not 
from decreased blood flow, but from increased demand.  No controls were studied in 
this paper and there was again the estimate of hepatic blood flow using a dye dilution 
technique.
The next study by Dahn et al (121) set out to characterize the changes in total liver 
blood flow in sepsis and also to assess whether different clearance methods gave a 
constant result.  The results demonstrated a significant increase in total hepatic blood                                                                                                      
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flow in patients with sepsis compared with normal volunteers who also had liver 
blood flow measurements made using three different clearance indicators.   
Esko Ruokonen et al(122) assessed blood flow distribution in patients with 
hyperdynamic septic shock and the effect of inotropes on this and oxygen transport.  
10 intensive care patients with a mean APACHE II score of 13 and hyperdynamic 
septic shock were compared to 11 postoperative cardiac surgery patients.  The control 
group were in the immediate postoperative phase following routine cardiac surgery 
and were still ventilated.  Total liver blood flow and oxygen consumption was 
measured in the septic patients while hypotensive and during inotrope therapy.  All 
patients with sepsis had increased total liver blood flow, compared to controls, even 
before inotropic support.  Dopamine increased total liver blood flow in all patients but 
the effect of noradrenaline (norepinephrine) was not uniform; total liver blood flow 
increasing in three and decreasing in two patients.  This paper proposed that regional 
blood flow changes cannot be predicted from systemic changes.  It also demonstrated 
that during the hypotension of septic shock, total liver blood flow was markedly 
increased, as was oxygen extraction.
As liver blood flow would appear to be so important in sepsis and its resolution a 
number of studies have attempted to characterize changes in liver blood flow with 
various inotropic or other metabolic agents.  In critically ill patients requiring 
inotropic support with noradrenaline, replacing noradrenaline with phenylephrine 
maintained systemic blood pressure but resulted in a fall in liver blood flow (123).  
The authors concluded that exogenous beta-adrenergic receptor stimulation 
determines total liver blood flow.  In a similar study dopamine and noradrenaline                                                                                                      
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were found to have similar haemodynamic effects on the splanchnic circulation; 
however adrenaline was felt to impair total liver blood flow (124).  The effect of 
dopexamine was studied in resuscitated septic shock patients and found it did not 
increase total liver blood flow.  Neither was a change in liver blood flow 
demonstrated with an acute increase in arterial CO2 (125) or fluid optimisation (126).  
N-acetylcysteine increased liver blood flow and liver function in sepsis(127) and this 
was thought to be due to an increase in cardiac output rather than a specific effect on 
liver blood flow.
The above papers agree that total liver blood flow is increased in systemic 
inflammation when compared to control groups.  They have all used hepatic vein 
cannulation and sampling of a clearance agent to estimate total liver blood flow.  They 
all examined at a single point in an intensive care stay.  The variability of liver blood 
flow in patients with sepsis was studied and the authors found that, in the 8 patients 
studied with stable mean arterial blood pressure considerable differences in the total 
liver blood flow were found, with a standard error of 31.1% at 5 minute intervals and 
28.6% at 2 hours (128).  No immediate clinical or prognostic value is claimed by any 
of the studies that estimate total liver blood flow and the placement of a hepatic 
venous catheter is not seen in normal clinical practice.  One study has suggested that 
the ratio of total liver blood flow over cardiac output may be prognostic, finding liver 
blood flow and cardiac output correlated in non-septic patients but a lower value in 
sepsis.  The ratio was also lower in non-survivors compared to survivors in the septic 
group.  It is difficult to place too much value on these findings as 33 patients were 
studied of whom only 16 were septic (129).                                                                                                     
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Ultrasound colour Doppler/ duplex measurement of hepatic arterial and portal venous 
flow in critically ill patients has only been reported in one paper(130).  30 patients 
were compared to 12 healthy subjects.  Increased total hepatic blood flow and portal 
venous blood flow was seen at 5 hours after the onset of sepsis but no significant 
difference compared to controls was demonstrated at 24 hours after onset of sepsis. 
No definition is given of ‘onset of sepsis’.  In all the other studies systemic 
inflammation is well established by the time measurements have been carried out.  It 
is difficult to measure changes in blood flow immediately after the inflammatory 
stimulus but we can infer from other studies in the literature discussed below what is 
likely to occur following tissue injury/infection.
Immediate changes in blood flow are more difficult to study, as an inflammatory 
stimulus is usually unpredictable.  The controlled trauma and tissue injury of surgery 
have been used in a number of studies to substitute for the inflammatory stimulus.  
Continual measurement of hepatic venous flow in the peri-operative period indicates
flow before and immediately after inflammatory stimulus of trauma (operation).  
Historically a 20% decrease in hepatic venous blood flow is seen with epidural 
anaesthetic alone and there is a further 10% decrease with the addition of inhaled 
anaesthesia (131;132).  
Studies in patients undergoing cholecystectomy have demonstrated a decrease in 
hepatic venous blood flow during laparoscopic surgery to around a third of the 
preoperative flow.  This recovers immediately after deflation of the 
pneumoperitoneum (132).  Open cholecystectomy did not significantly alter liver 
blood flow in the perioperative period.  This demonstrates that with modern                                                                                                      
53
anaesthesia, liver blood flow changes during open surgery are not significant but 
pneumoperitoneum affects liver blood flow.
Other researchers have used cytokines found in high levels during inflammation to 
simulate systemic inflammation.  In one such study we see that healthy volunteers 
administered a continual infusion of IL-6 demonstrate a dramatic increase in total 
liver blood flow (133).  A mean total liver blood flow of 1300ml/min increases 
significantly by an hour and plateau by two hours at 1900ml/min.  The plasma level of 
IL-6 achieved was lower than that seen in systemic inflammation but points towards 
cytokines being mediators of haemodynamic changes, independent of catecholamines 
that are known to affect blood flow and are found at higher levels in systemic 
inflammation.  As we have discussed, in patients with a systemic inflammatory 
response the regulation of liver blood flow is complex and the presence of elevated 
levels of counter-regulatory hormones and certain cytokines are likely to be important 
factors in this regulation.                                                                                                     
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AIMS
The aims of the project were to:
1. Establish the effects of non-small cell lung cancer and alcoholic hepatitis on 
hepatic arterial and portal venous blood flow and correlate this with level of 
systemic inflammatory response as assessed by serum C-Reactive Protein.
2. Examine the hepatic arterial and portal venous blood flow response to a single 
inflammatory stimulus.
3. Evaluate longitudinal changes in hepatic arterial and portal venous blood flow 
in critically-ill patients during their intensive care admission.                                                                                                     
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Chapter 2:  Measurement of liver blood flow in 
humans using the colour Doppler/ duplex 
ultrasound technique.                                                                                                     
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2.1  Introduction
Adequate blood flow is essential to the cellular function of the liver.  In humans 
reliable techniques to measure liver blood flow are essential to ascertain whether 
changes in hepatic function are primarily due to altered cellular activity or secondary 
to changes in blood flow.  A number of methods for the measurement of liver blood 
flow have been described in man.  However in the main they have been unable to 
differentiate the relative contributions of hepatic arterial and portal venous flow to the 
total liver blood flow.  Most commonly described in investigating alterations in liver 
blood flow in humans, whether in health or disease, is the clearance technique using 
markers that are cleared by the liver.  Liver blood flow is then calculated by the “Fick 
principle,” measuring marker concentration entering the liver and subtracting the 
concentration in the blood leaving the liver.  This allows calculation of blood flow 
through the organ per minute; dividing total removal rate by the amount removed 
from each millilitre of blood that transverses the organ.
By using an infusion to obtain a constant plasma level of the marker, a steady state is 
achieved where the infusion rate of a marker equals the extraction rate (total removal 
rate).  The concentration of marker before the liver is measured from arterial or 
peripheral venous sampling; however the concentration of marker leaving the liver 
can only be measured by the relatively invasive cannulation of the hepatic vein.
A number of clearance agents have been studied in the estimation of blood flow, the 
most common being indocyanine green.  However, this may give an overestimation of 
hepatic blood flow as the extraction fraction of indocyanine green is reduced in sepsis                                                                                                       
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(121;134;135).  This may be due to sepsis-induced changes in hepatocellular function 
in centrilobular locations leading to non-exchanging sinusoidal lesions and a 
physiological shunt (136).  Galactose has also been studied and has similar problems 
of decreased clearance in sepsis (136-138) as well as an increased extrahepatic 
clearance in sepsis (137).  The ideal indicator would be cleared on a single pass of the 
liver, not be affected by the disease state and have no extrahepatic clearance.  Such an 
agent has not yet been found.
Other methods have been used to measure blood flow to the liver and this has been 
studied in the field of metastatic liver cancer from gastrointestinal origin.  Dynamic 
flow scintigraphy is a nuclear medicine technique that uses Technetium-99 labelled 
colloid from the patients own blood.  Gamma cameras are placed over the right liver 
and detect flow in the first and second eight-second period following injection.  The 
first period was used to represent arterial flow and the second period the portal venous 
flow.  Using this method it was suggested that patients with metastatic liver cancer 
had a higher proportion of total liver blood flow from the hepatic artery than patients 
without liver metastasis (139).  Some authors have reported poor reproducibility and 
therefore dynamic flow scintigraphy has not been incorporated into routine clinical 
use (140;141).  However, its use is limited to those patients who can be safely 
transported to the nuclear medicine department.
Following from this Miles and co-workers (142) described a method based on single-
slice dynamic computerized tomography (CT) scanning.  Measurements of 
enhancement were performed after a bolus injection of contrast medium by placing 
regions of interest over the liver, aorta and spleen.  Estimates of hepatic arterial and                                                                                                      
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portal venous liver perfusion were obtained by dividing the maximum slope of the 
liver enhancement curve by the peak aortic enhancement, the splenic peak being used 
to separate the arterial and portal venous phases of enhancement.  Significant changes 
in perfusion were detected in patients with various conditions, including liver 
metastases.  However, its use is limited to those patients who can be safely 
transported to the radiology department.  
Therefore, there is a continuing interest in measuring liver blood in the ill patient who 
the above techniques are in the main not suitable for making multiple and serial 
measurements.  More recently improvements in ultrasound technology have permitted 
bedside, non-invasive direct measurement of blood flow in the ill patients.  The 
introduction of colour Doppler/ duplex has enabled the measurement of hepatic 
arterial and portal venous blood flow in such patients (143;144).  As above much of 
the use of this technology has focused on the prediction of hepatic metastasis in 
gastrointestinal cancers (145-147).  While initial results from one centre were 
promising, again reproducibility has been a problem (148;149).  However, more 
recently Duplex Doppler ultrasound of the hepatic artery has also been studied in 
hepatitis and an increased flow in alcoholic hepatitis is seen compared to viral 
hepatitis (150;151).  Moreover, measurement of the hepatic arterial flow and portal 
venous flow has been found to be reproducible within and between observers (152).
The aim of the present study was to examine the reproducibility of hepatic arterial 
flow and portal venous flow measurements using Colour Doppler Duplex ultrasound.                                                                                                     
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2.2  Subjects and methods
Subjects
Intra-observer error
Seven healthy volunteers underwent repeated scanning (Table 2.1).  Hepatic arterial 
blood flow and portal venous blood flow were measured in ml/min as described 
below.  All measurements were taken after a minimum of 5 hours fasting at 
approximately the same time of day each day.  The subjects’ median age was 23 years 
(range 23-25) and male: female ratio was 2:5.  Measurement values were saved 
directly to the ultrasound scanner to avoid unconscious bias during scans and data was 
analysed at the end of the procedure.  Formal consent was not sought but all 
volunteers were medical doctors who gave oral consent and understood the 
investigation being performed.
Inter-observer error
Ultrasound scans of 14 patients, chosen at random, were performed by Dr John 
MacQuarrie and myself.  Two studies were excluded by one observer due to problems 
locating the common hepatic artery and hence DPI values were unobtainable, a third 
patient was excluded due to incomplete examination.  Each subject was scanned using 
the same Ultrasound scanner and methods as described below.  As the scans were 
performed separately, each observer was blind to the placement of Doppler callipers 
and cross sectional area measurements.                                                                                                     
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Methods
Duplex/colour Doppler ultrasound of the hepatic artery was carried out using an 
appropriate ultrasound scanner with colour Doppler US function and a 3.5-MHz 
curvilinear probe.  The patients were examined in the supine position and the common 
hepatic artery was identified along its longitudinal axis in the epigastrium by a 
transverse scan.  The Doppler cursor was placed over the lumen of the artery, as near 
to the origin as possible, at the point where the artery first becomes horizontally 
straight.  The Doppler sample volume and the beam angle are adjusted and the time 
average velocity was calculated over at least 4 cardiac cycles.  The cross sectional 
area was measured at the same point as the velocity, at right angles to this.  The portal 
vein was best viewed along its longitudinal axis with a right lateral intercostal 
approach and velocity was measured where this first became intrahepatic but before 
branching.  The cross sectional area was best measured in inspiration via a subcostal 
approach.  Three measurements were taken at each study and an average was used to 
calculate flow.
Blood Flow (ml/min)
= (cross sectional area) x (time average mean velocity) x (60)
= XSA (cm
2) x TAM (mls
-2) x 60
2.3  Results
Intra-observer error
Values for control of variance were calculated and an intra-observer error of around 
10% was seen in hepatic arterial and portal venous blood flow (Table 2.2).  These 
results demonstrate good reproducibility of the method in the hands of one operator.                                                                                                       
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Error in the previously published validation (152) study of the technique showed a 
higher variation in blood flow measurements (hepatic arterial flow 12% and 15% and 
portal venous flow 20% and 18%).
Inter-observer error
The mean difference (standard deviation) between the DPI values measured by both 
observers was -0.01 (0.07).  The Intra-class correlation coefficient was 0.71, 
Spearman rank correlation coefficient was 0.75 (p=0.008) and conventional (Pearson) 
correlation coefficient was 0.70 (p=0.016), 95% Confidence Intervals were -0.05 and 
0.03 (Table 2.3).
2.4  Discussion
We can compare measurements in this study to total liver blood flow values than have 
been previously published (Table 2.4).  In these studies full details of the control 
group are not given and we cannot assume they are completely healthy volunteers.  
Mean total liver blood flow in our group of healthy volunteers was 2233ml/min, 
which is much higher than previously published controls.  The explanation for this is 
likely to be explained by the shorter period of fasting before scanning in the group of 
volunteers.  It was felt that if a repeatable test could be performed, the consequence of 
overestimating hepatic arterial and portel venous blood flow would not influence the 
results of studies where patients were acting as there own controls.  Previous studies 
have estimated total liver blood flow using different methods and direct comparisons 
should not be made.  In the validation study by Oppo and Leen, blood flow 
measurements were lower in their subjects than in this study (Table 2.5), however                                                                                                      
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their population was strictly fasted for 12 hours before being studied and this may 
account for the differences.
The common hepatic artery arises as a branch of the coeliac trunk and is a single 
artery in over 80% of the population.  Variant anatomy, for example a right hepatic 
artery arising from the superior mesenteric artery, was not identified and in the study 
subjects we would have expected to see a number of individuals with variant 
anatomy.  It is accepted that measurement of the hepatic artery in these studies may 
have missed part of the liver blood supply, however it would have little impact on the 
results of the studies as we have discussed above, if flow in the same artery was 
repeatedly measured this would have little impact on the serial measurements.
Intra-observer error was within that of the previously published validation study 
(152).  Inter-observer error also fell within previously published values.  Having 
validated the technique it was felt appropriate to continue the study of patient groups 
with inflammatory conditions.  A low intra-observer error would allow us to assess 
changes in liver blood flow in both the hepatic artery and portal vein within cohorts 
where altered total liver blood flow had been demonstrated and published.                                                                                                     
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Figure 2.1 Colour Doppler / Duplex ultrasound of common hepatic artery
Typical waveform of pulsatile flow in the hepatic artery just outside the liver after the 
gastroduodenal artery leaves the common hepatic artery.                                                                                                     
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Figure 2.2 Colour Doppler / Duplex ultrasound of portal vein 
Flatter flow in the portal vein just outside the liver before it bifurcates.                                                                                                     
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Table 2.1 
Intra-observer error; repeated scans in healthy volunteers
Control Scan No. HA XSAHA TAM PV XSA PV TAM HABF PVBF
A 1 0.24 43.1 1.22 24.8 621 1815
2 0.25 36.1 1.17 19.4 542 1362
B 1 0.23 32.3 1.06 28.7 446 1825
2 0.25 36.1 1.09 29.2 542 1910
3 0.23 40.9 1.04 25.7 564 1604
C 1 0.35 18.8 1.45 14.8 395 1288
2 0.36 16.4 1.40 14.4 354 1210
3 0.35 20.1 1.49 13.4 422 1198
D 1 0.32 30.1 1.64 26.5 578 2608
2 0.30 28.9 1.60 24.1 520 2314
3 0.33 25.7 1.57 22.5 509 2120
E 1 0.28 34.9 1.32 19.4 586 1536
2 0.33 36.1 1.30 17.5 715 1365
3 0.29 36.9 1.26 19.6 642 1482
F 1 0.40 1.40 18.0 1512
2 0.39 1.38 15.3 1267
3 0.39 1.37 14.4 1184
G 1 0.26 36.1 1.32 20.1 563 1592
2 0.28 28.9 1.35 18.0 486 1458
3 0.30 34.1 1.30 28.7 614 2239
HA XSA- hepatic artery cross sectional area
HA TAM- hepatic artery time average mean velocity
PV XSA- portal venous cross sectional area
PV TAM- portal venous time average mean velocity
HABF- hepatic arterial blood flow ml/min
PVBF- portal venous blood flow ml/min                                                                                                     
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Table 2.2
Intra-observer error; control of variance in healthy volunteers
HABF PVBF TLBF
mean Sd CV % mean Sd CV % Mean Sd CV %
Subject
A 581.07 55.96 9.63 1588.62 320.66 20.18 2169.69 376.62 17.36
B 517.22 62.96 12.17 1779.56 158.05 8.88 2296.78 143.28 6.24
C 390.38 34.15 8.75 1231.72 48.74 3.96 1622.10 59.31 3.66
D 535.66 37.03 6.91 2346.90 245.75 10.47 2882.56 281.76 9.77
E 647.72 64.42 9.95 1461.08 87.59 5.99 2108.80 25.14 1.19
F 1320.84 170.69 12.92
G 554.16 64.61 11.66 1762.84 417.43 23.68 2317.00 475.58 20.53
Mean 537.70 53.19 9.84 1641.65 206.99 12.30 2232.82 226.95 9.79                                                                                                     
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Table 2.3  
Inter-observer variation between liver blood flows measured by Doppler ultrasound.
TLBF Total liver blood flow (ml/min); HAF Hepatic artery flow volume (ml/min); 
PVF  Portal  venous flow  volume  (ml/min);  HATAM  Hepatic  artery  time-averaged 
velocity (cm/s); HAXSA Hepatic artery cross sectional area (cm
2); PVTAM Portal 
vein time-averaged velocity (cm/s); PVXSA Portal cross sectional area (cm
2).
No.
TLBF 
1
TLBF 
2
HAF 
1
HAF 
2
PVF 
1
PVF 
2
HA
TAM 
1
HA
TAM 
2
HA 
XSA 
1
HA
XSA 
2
PV
TAM 
1
PV
TAM 
2
PV
XSA 
1
PV
XSA
2
1 750.00 670.50 324.00 346.50 426.00 706.92 22.50 27.50 0.24 0.21 10.00 13.70 0.71 0.86
2 762.00 585.84 207.00 378.84 555.00 590.64 15.00 15.40 0.23 0.41 12.50 10.70 0.74 0.92
3 685.23 354.03 166.83 187.20 518.40 1035.72 8.30 12.00 0.34 0.26 7.20 12.60 1.20 1.37
4 602.49 359.76 86.52 273.24 515.97 1109.76 10.30 20.70 0.14 0.22 9.10 13.60 0.95 1.36
5 990.96 524.40 191.76 332.64 799.20 1382.40 18.80 19.80 0.17 0.28 14.80 18.00 0.90 1.28
6 439.20 146.52 48.60 97.92 390.60 615.60 13.50 10.20 0.06 0.16 9.30 10.80 0.70 0.95
7 915.54 386.76 193.38 193.38 722.16 722.16 29.30 29.30 0.11 0.11 10.20 10.20 1.18 1.18
8 1233.9
0 716.58 348.30 368.28 885.60 1098.36 21.50 19.80 0.27 0.31 18.00 16.20 0.82 1.13
9 626.40 459.00 135.00 324.00 491.40 922.32 9.00 18.00 0.25 0.30 9.00 12.60 0.91 1.22
10 1203.6
6 475.44 153.90 321.54 1049.7
6 1069.20 17.10 23.30 0.15 0.23 16.20 16.20 1.08 1.10
11 1276.3
8 308.04 135.24 172.80 1141.1
4 1350.00 9.80 14.40 0.23 0.20 14.30 18.00 1.33 1.25                                                                                                     
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Table 2.4
Previously published control values
n group TLBF 
L/min/m2
TLBF 
1.73L/min/m2
Measured by
Bradley 
1945(153)
23 syphilis 0.87 1.5 Bromsulphalein 
clearance
Dahn 
1990(121)
10 controls 0.74 1.28 Indocyanine green 
clearance
Lyngso 
2002(133)
7 controls 1.3 Indocyanine green 
clearance
Wilmore 
1980(120)
historical 
controls
0.63-0.85 1.1-1.5 Not stated                                                                                                     
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Table 2.5 
Comparison of results with previous validation study (152)
Parameter Observer 1 Observer 2 Table 2.1 data
HA XSA (cm2) 0.22 (0.10) 0.25 (0.13) 0.31 (0.05)
HA TAM (cm/sec) 26.3 (8.9) 24.3 (10.4) 31.5 (7.6)
HA blood flow 
(ml/min)
361 (267) 367 (254) 535 (94)
PV XSA (cm2) 1.24 (0.30) 1.36 (0.30) 1.34 (0.17)
PV TAM (cm/sec) 13.7 (5.0) 13.1 (4.4) 20.73 (5.2)
PV blood flow 
(ml/min)
1005 (407) 1052 (403) 1644 (411)
All values are mean and standard deviation                                                                                                     
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Chapter 3 :  The relationship between components 
of liver blood flow and the systemic inflammatory 
response in benign and malignant disease.                                                                                                     
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3.1  Introduction
The liver plays an important role in the propagation, regulation and resolution of the 
systemic inflammatory response.  Hepatocytes are recognised to be an important site 
of the increased gluconeogenesis and production of acute phase proteins in injury or 
infection.  Therefore the liver is recognised to be hypermetabolic during systemic 
inflammation (154).  The liver blood flow responses to injury or infection have not 
been well documented.
In malignant disease colour Doppler/duplex ultrasound of the hepatic artery and portal 
vein have been used to demonstrate alterations in liver blood flow in gastrointestinal 
cancers and breast cancers (145).  In patients with benign disease such as alcoholic 
hepatitis it has been reported that both the diameter and the velocity of blood through 
the hepatic artery, and therefore blood flow, were increased compared with a control 
group (151).  
It is now recognised that patients with advanced cancer undergo a series of 
pathophysiological changes, many of which are now accepted to be part of the 
systemic inflammatory response (1;155).  Similarly, in benign disease such as 
alcoholic hepatitis systemic inflammatory response is recognised to play an important 
role in the pathophysiological of the disease (156).  Both in malignant disease, such as 
non-small cell lung cancer, and benign disease, such as alcoholic hepatitis, the 
presence of systemic inflammation has been demonstrated to be associated with 
poorer survival (157-160).                                                                                                       
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The aim of the present study was to examine the relationship between components of 
liver blood flow and the systemic inflammatory response in patients with benign and 
malignant disease.                                                                                                       
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3.2  Subjects and methods
Subjects
Patients admitted to the Royal Infirmary, Glasgow with benign (alcoholic hepatitis) or 
malignant disease (inoperable non-small cell lung cancer) were studied.  The 
diagnosis and aetiology of hepatitis was determined on the basis of clinical, 
biochemical, immunological, virological and imaging findings.  Also, control subjects 
were recruited from patients prior to surgery for non-malignant and non-inflammatory 
conditions such as abdominal wall hernia, varicose veins and lower limb joint 
replacement.  These patients underwent ultrasound examination to measure hepatic 
arterial and portal venous blood flow and blood was sampled for C-reactive protein 
measurement.
The study was approved by the research ethics committee of North Glasgow 
University Hospitals NHS Trust.  
Liver blood flow
Hepatic arterial and portal venous blood flow measurements were carried out as
previously described (see Chapter 2.2).  This was validated as described in Chapter 2.  
Measurements of the common hepatic artery velocity and cross sectional area were 
made close to the origin of the vessel.  No major anatomical variations were 
encountered.
Statistical analysis
The  relationships  between  liver  blood  flow  and  demographic  and  biochemical 
characteristics were analysed using the Kruskal-Wallis and Mann-Whitney tests and                                                                                                      
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Spearman’s rank correlation analysis as appropriate.  Statistical analysis was carried 
out using SPSS for Windows (SPSS Inc., Chicago, USA).                                                                                                     
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3.3  Results
The clinicopathological characteristics of the control and patients with benign or 
malignant disease are shown in Table 1.  All of the patients with NSCLC were 
inoperable and receiving palliative chemotherapy.  Five patients had TNM stage IV, 4 
had stage III disease and one patient had stage II disease.  The latter patient was 82 
and was not considered suitable for surgery.  In the alcoholic hepatitis group 2 
patients had Child Pugh grade B and 5 patients had C disease.  The patients with 
alcoholic hepatitis were younger (p<0.05), had higher hepatic arterial blood flow 
(p<0.05) and had higher C-reactive protein concentrations (p<0.001).
The relationship between clinicopathological characteristics and liver blood flow is 
shown in Table 2.  Hepatic arterial blood flow was significantly associated with 
disease state (p<0.05) and an elevated C-reactive protein concentration (p<0.001).  
Portal venous blood flow was only significantly associated with age (p<0.05).  Total 
liver blood was significantly associated with an elevated C-reactive protein 
concentration (p<0.05). 
Measurements for all patient groups are listed in appendix 1.                                                                                                     
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3.4  Discussion
The results of the present study would indicate for the first time that, in groups with 
increasing levels of systemic inflammation hepatic arterial blood flow is increased.  In 
particular, it would appear that an increased hepatic arterial blood flow was associated 
with an elevated C-reactive protein concentration.  This would suggest a role for the 
systemic inflammatory response in the regulation of hepatic arterial blood flow in the 
diseased state.  
.
The results of the present study are consistent with previous work which has shown 
increases in total liver blood flow in patients with acute illness.  Wilmore and 
colleagues (1980) reported a stepwise increase in total liver blood flow, as calculated 
by indocyanine green clearance, in intensive care patients with systemic inflammatory 
response syndrome, patients with sepsis and patients with multi-organ dysfunction 
syndrome(120).  However, the method used to assess liver blood flow did not provide 
information about the hepatic arterial and portal venous blood flow.  
The effect of lesser degrees of systemic inflammation on liver blood flow are less well 
understood.  Research in patients with malignant disease has indicated that alterations 
in liver haemodynamics and increase in hepatic arterial blood flow are associated with 
more aggressive disease, metastasis and poorer outcome (146;161;162).  While 
systemic inflammation and particularly C - reactive protein have also been linked to 
histologically more aggressive cancer and poorer outcome(157;163;164), until the 
present work no one has shown a link between systemic inflammation and liver blood 
flow changes.  In benign disease, alcohol induced hepatitis provokes an increase in 
hepatic arterial blood flow(151).  This has been demonstrated to differentiate between                                                                                                      
77
alcohol induced and viral hepatitis, but again, no link between systemic inflammation 
and liver blood flow has been previously reported.  A body of work is emerging that 
nitric oxide is a mediator of changes in liver blood flow in alcohol induced hepatitis 
and accounts for the development of portal hypertension.  In rats inhibition of nitric 
oxide synthesase leads to an increase in portal pressure and this is felt to be 
translatable to humans.
Studies with pro-inflammatory cytokines in cancer trials and healthy volunteers show 
increases in total liver blood flow which peak at 2 hours after commencement of 
infusion of IL-6(133).  This would suggest a direct association between systemic 
inflammation and liver blood flow changes.  However, these results do not inform us 
of the underlying basis of these observations.  However, it may be that these changes 
in liver blood flow are as a result of relative hypoxia in a liver resulting in the 
increased production of hypoxia inducible factor which is recognised to upregulate 
interleukin-6 production (165) and thus C-reactive protein concentrations in the 
circulation (1). 
The present study does not define the timing of the changes in the components of liver 
blood flow but does demonstrate for the first time the relative contributions to total 
liver blood flow.  It would appear from this small study that it is the contribution from 
the hepatic arterial circulation that accounts for liver haemodynamic changes in 
systemic inflammation.                                                                                                     
78
Table 1.  The clinicopathological characteristics and liver blood flow in controls, non-small cell lung cancer, and alcoholic hepatitis. 
Controls
(n=18)
NSCLC
(n=10)
AH
(n=7) 
P-value
Age    <65yrs
        65-74yrs
          >75 yrs
8
3
7
4
3
3
7
0
0 0.032
Sex       Male
          Female
9
9
8
2
6
1 0.059
HABF (ml/min)
PVBF (ml/min)
TLBF (ml/min)
366
1361
1759
634
1335
1826
738
924
1470
0.014
0.267
0.713
C-reactive protein (mg/l) <6 (<6-8) 16 (<6-123) 34 (<6-94) <0.001
C-reactive protein
    <10mg/l
   >10mg/l
18
0
2
8
1
6 <0.001
HABF, hepatic arterial blood flow; PVBF, portal venous blood flow and TLBF, total liver blood flow expressed as median.  CRP, C-reactive 
protein; NSCLC, non-small cell lung cancer; AH, alcoholic hepatitics                                                                                                     
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Table 2.  Liver blood flow in controls, non-small cell lung cancer, and alcoholic hepatitis. 
n HABF (ml/min) P-value PVBF (ml/min) P-value TLBF (ml/min) P-value
All patients 35 436 (98-1138) 1319 (616-2572) 1804 (714-3141)
Age    <65yrs
        65-74yrs
          >75 yrs
19
6
10
436 (98-1138)
511 (295-689)
394 (302-1115) 0.961
1026 (616-2174)
1376 (674-1620)
1398 (922-2572) 0.032
1467 (714-2904)
1933 (969-2309)
1835 (1246-3141) 0.199
Sex       Male
          Female
23
12
458 (193-1115)
380 (98-1138) 0.331
1097 (663-2572)
1351 (616-1620) 0.424
1804 (915-3141)
1799 (714-2595) 0.972
Controls
NSCLC
AH
18
10
7
366 (98-689)
664 (295-1115)
738 (242-1138) 0.014
1361 (616-2572)
1335 (663-2174)
924 (688-1457) 0.267
1759 (714-3141)
1826 (969-2939)
1470 (1093-2595) 0.713
C-reactive protein
    <10mg/l
   >10mg/l
21
14
363 (98-689)
705 (242-1138) >0.001
1309 (616-2572)
1321 (732-2174) 0.637
1700 (714-3141)
1936 (1166-2939) 0.031
Results expressed as median (range). HABF, hepatic arterial blood flow; PVBF, portal venous blood flow; TLBF, total liver blood flow; CRP, 
C-reactive protein; NSCLC, non-small cell lung cancer; AH, alcoholic hepatitics                                                                                                     
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Chapter 4 :  The relationship between hepatic 
arterial blood flow, portal venous blood flow and 
time following elective arthroplasty.                                                                                                     
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4.1  Introduction
It has long been recognised that the liver is an essential organ in the propagation, 
regulation and resolution of systemic inflammation(154).  There is some evidence that 
total liver blood flow is increased as part of the systemic inflammatory 
response(14;117;120;122).  There are also a few studies that have shown that blood 
flow and metabolic changes are mediated, in part, by the counter-regulatory hormones 
adrenaline, cortisol and glucagons (10;11;98;101) and influenced by the presence of 
pro-inflammatory cytokines such as interleukin-6 (16;133).  
To date few studies have examined the temporal nature of the changes in liver blood 
flow following an inflammatory stimulus (14).  Also, to our knowledge, there have 
been no studies, in humans which have reported the changes in hepatic arterial and 
portal venous components of total liver blood flow.  
In order to examine the effects of the systemic inflammatory response on metabolism 
in humans, a number of workers have used elective surgical models such as 
cholecystectomy or joint replacement (65;166-168).  In the case of measuring the 
components of liver blood flow an abdominal operation may compromise the ability 
to carry out ultrasound measurements and may directly influence liver blood flow.  
However, the elective operations of hip and knee replacement are unlikely to 
compromise hepatic arterial or portal venous blood flow measurements directly and 
do provide a standard inflammatory stimulus (15-16).
The aim of the present study was to examine the temporal relationship of hepatic 
arterial blood flows in patients undergoing elective hip or knee arthroplasty.                                                                                                     
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4.2  Subjects and Methods
Patients
Patients undergoing primary lower limb arthroplasty at the Royal Infirmary, Glasgow 
were studied.  Prior to surgery patient age, sex and anti-inflammatory medication was 
recorded as well as C-reactive protein concentration.  
A baseline ultrasound was performed the evening before theatre to measure hepatic 
arterial and portal venous flow.  All patients underwent standard anaesthesia including 
general and epidural anaesthetic.
Immediately after transfer from theatre to the anaesthetic recovery room, the first 
post-operative measurement of liver blood flow was made.  This was designated the 
zero hour scan.  Further ultrasound measurements of liver blood flow were performed 
at two hourly intervals for the next six hours.  A final scan was performed at 24 hours 
from the zero hour scan.
The study was approved by the research ethics committee of North Glasgow 
University Hospitals NHS Trust.  All subjects were informed of the purpose and 
procedure of the study and all gave consent.
Liver blood flow
Measurements of hepatic arterial and portal venous blood flow were performed using 
an HDI 5000 (Philips-ATL, Bothell, WA, USA) ultrasound system with duplex-
colour Doppler and a 3.5 MHz curvilinear scanhead as previously described (see                                                                                                      
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Chapter 2).  Briefly, hepatic arterial and portal venous blood flows were calculated as 
the product of time averaged velocity and the cross sectional area of the vessel.  Total 
liver blood flow was calculated as the sum of hepatic arterial and portal venous blood 
flows.  
Statistical analysis
Data are presented as median and range.  Data from different time periods were tested 
for statistical significance using the Friedman test and where appropriate, comparisons 
of data from different time periods were carried out using the Wilcoxon signed rank 
test.  Analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA).                                                                                                     
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4.3  Results
Twenty patients were included in the study.  The majority of patients were female, 
over the age of 70 years and had a C-reactive protein concentration in the normal 
range.  Four patients with rheumatoid arthritis were included in the study and the 
remainder were osteoarthritics.  Nine patients were receiving non-steroidal anti-
inflammatory or COX-II inhibitors, 2 patients were on low dose prednisolone and two 
were taking immunosupressors (gold, sulphasalazine and methotrexate).  Three 
patients were excluded from the analysis as they had no post-operative Doppler scans.  
This was due to peri-operative confusion or illness.  A further 5 patients only had one 
other post-operative scan.  Twelve patients had scans carried out at all the time-points. 
All patients had an uneventful perioperative period.  The patient characteristics and 
longitudinal measurements of liver blood flow are shown in Table 1.
Hepatic arterial blood flow increased in the post-operative period (p<0.05), a peak at 
4 hours (Figure 1).  In contrast, portal venous flow fell in the post-operative period 
(p<0.001), a trough immediately post-operative (Figure 2).  The net effect was a fall 
in total liver blood flow (p<0.05) in the immediate post-operative period.  
Paired comparison of pre-operative and 24 hour hepatic arterial flows showed no 
difference (p=0.753) and therefore hepatic arterial flow returned to pre-operative 
values.  In contrast, paired comparison of pre-operative and 24 hour portal venous 
flows showed that portal venous flow fell (p=0.046) and therefore portal venous flow 
had not returned to pre-operative values. 
Liver blood flow measurements for each patient are listed in appendix 2.                                                                                                     
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4.4  Discussion
The results of the present study show, for the first time, that there is an immediate 
post-operative reduction in portal venous blood flow followed by an increase in 
hepatic arterial blood flow resulting in a reduction of total liver blood flow in patients 
following elective knee arthroplasty.  
The basis of these observations is unclear.  However, the classical neuro-endocrine 
mediated ‘fight or flight’ response to tissue injury is known to occur rapidly and is 
thought to divert blood away from tissues such as the splanchnic organs which are not 
required for this response.  The results of the present study confirm that there is 
indeed a reduction in total liver blood flow.  
However, there was also an increase in hepatic arterial blood flow following tissue 
injury. The mechanism by which hepatic arterial blood flow is increased is not clear.  
There are a number of possible explanations for later transient increase in hepatic 
arterial blood flow.  
It could be due to the technical aspects of the operative procedure itself.  However, 
modern anaesthesia is not thought to affect liver blood flow (132). This has been 
studied in patients undergoing laparoscopic surgery where the pneumoperitoeum was 
considered to have the potential to compromise splanchnic blood flow and thus liver 
function in the post-operative period.  It has been demonstrated that in elderly patients 
undergoing laparoscopic surgery there is a decrease in total liver blood flow that is not 
demonstrated in the younger patients or at open surgery.  Thoracic epidurals have 
been demonstrated to reduce total liver blood flow, lower epidurals such as these                                                                                                      
87
patients received have not shown this effect on liver blood flow (132).  It could be 
simply a passive reactive response to a fall in portal venous blood flow.  Venous 
transmural pressure feeds back to the arterioles in the liver decreasing arterial 
resistance and increasing blood flow (100). As discussed in the introduction the 
strongest influence on liver blood flow is the metabolic intrinsic control.  Increased 
products of metabolism will act locally to vasodilate and increase blood flow 
(100;101).  Feeding is demonstrated to increase liver blood flow (99) but in this study 
all patients were fasting during the first 6 hours and its influence is controlled in this 
study.
Alternatively, the increase in hepatic arterial blood flow may be as part of the 
systemic inflammatory response to injury.  For example, following an inflammatory 
stimulus there is good evidence that the liver becomes hypermetabolic (1) and has an 
increased demand for oxygen which an increase in hepatic arterial flow would 
provide.  Also, it is of interest that in the profound systemic inflammatory response of 
the critically-ill patients increases in total liver blood flow have been reported 
(79;120-122).  Further evidence of the role of the systemic inflammatory response is 
that an infusion of IL-6 into healthy volunteers was associated with an increase in 
total liver blood flow (11).  Therefore, it would appear that the increase in hepatic 
arterial blood flow seen in the present study may be a systemic inflammation driven 
response.                                                                                                     
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Table 1  Liver blood flow following lower limb arthroplasty. 
Pre-op
(n= 20)
Post-op 
Immediate
(n=17)
Post-op
2hr
(n=13)
Post-op
4hr 
(n=12)
Post-op
6hr
(n=12)
Post-op
24hr
(n=13)
Pre-op- 24hr 
Friedman
(P-value)
Age 72 (40-83)
Sex (M:F) 8:12
Disease (OA:RA) 16:4
C-reactive protein (mg/l) 6 (6-6)
HABF (ml/min) 412 
(233-687)
432
(262-640)
484
(262-667)
546
(275-899)
412
(259-833)
469
(253-689)
0.038
PVBF (ml/min) 1419
(869-2798)
979
(454-1413)
1251
(708-1555)
1209
(553-2183)
1333
(810-1952)
1424
(810-1771)
<0.001
TLBF (ml/min) 1898
(1102-3423)
1538
(762-1965)
1756
(971-2222)
1734
(1224-2822)
1760
(1069-2785)
1830
(1063-2428)
0.012
OA osteoarthritis, RA rheumatoid arthritis, HABF, hepatic arterial blood flow; PVBF, portal venous blood flow and TLBF, total liver blood flow 
expressed as median (range), C-reactive protein expressed as median (IQ range)                                                                                                     
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__
Figure 1 demonstrates changes in median hepatic arterial blood flow in ml/min (y-
axis) over the time points in the study (x-axis).  Time points are ha base= pre-
operative, ha0= immedialty post-operative, ha2= 2 hours post-op, ha4= 4 hours post-
op, ha6= 6 hours post-op and ha24= 24 hours post-op.
A peak in hepatic arterial blood flow is demonstrated at 4 hours post-operatively.
ha24 ha6 ha4 ha2 ha0 ha base
9
800
600
400
200
Figure 1.  Pre- and post-operative hepatic arterial blood flow 
measurements in patients undergoing lower limb arthroplasty
Hepatic 
arterial 
blood 
flow 
(ml/min)                                                                                                     
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Figure 2.  Pre- and post-operative portal venous blood flow measurements in 
patients undergoing elective knee arthroplasty
__
Figure 2 demonstrates changes in median portal venous blood flow in ml/min (y-axis) 
over the time points in the study (x-axis).  Time points are pv base= pre-operative, 
pv0= immedialty post-operative, pv2= 2 hours post-op, pv4= 4 hours post-op, pv6= 6 
hours post-op and pv24= 24 hours post-op.
Portal venous blood flow falls immediately post-operatively and then gradually 
recovers over time.91
Chapter 5 :  Longitudinal study of hepatic arterial 
and portal venous blood flow in the critically ill 
patient.92
5.1  Introduction
In chapters 3 and 4 we have demonstrated that an increase in liver blood flow in a 
variety of patient groups was associated with the presence of a systemic inflammatory 
response and these changes were predominantly influenced by an increase in the 
hepatic arterial component of the total liver blood flow.  As described in the 
introduction (Chapter 1), systemic inflammation can be present to a degree that it 
compromises homeostasis and organ function and therefore organ support is required.  
At this extreme of systemic inflammation, patients require support of their multi-
organ dysfunction syndrome in the critical care setting.  
As described in the introduction (Chapter 1) the liver plays a crucial role in the 
regulation of the systemic inflammatory response and therefore, its appropriate 
functioning becomes essential for patient outcome.  It has long been recognised that 
liver dysfunction in intensive care patients is associated with poor outcome and blood 
flow to the liver is therefore of great importance (80-85).  The relative inaccessibility 
of the portal vein and hepatic artery to non-invasive monitoring has resulted in fewer 
studies in this area than would be perhaps expected.  The few human studies described
in the introduction (Chapter 1) indicate that total liver blood flow is increased in the 
intensive care setting (9;79;120-122), but give no information on the components of 
the total liver blood flow or how this changes over the course of the critical illness.
On the basis of the results obtained in Chapters 3 and 4 it might be anticipated that 
there would be an increase in hepatic arterial blood flow in intensive care patients and 
that the increase in hepatic arterial blood flow would reflect the magnitude of the 
systemic inflammatory response.  Therefore, the aim of the present study was to 93
examine the longitudinal relationship between hepatic and portal venous blood flows 
and the systemic inflammatory response in patients with critical illness.94
5.2  Subjects and Methods
Patients
Patients (n= 31) admitted to the intensive care unit at Glasgow Royal Infirmary over a 
one and a half year period were considered for inclusion in the study.  The patients 
recruited were predominantly male (58%), general and vascular surgical patients 
(52%), with only 4 (13%) medical patients (Table 1).  
Patients with pre-existing liver dysfunction, metastatic liver disease, or who had burns 
or a wound over the right upper quadrant of the abdomen and where scanning would 
be uncomfortable or an infection risk were excluded from study.
The study was approved by the local research and ethics committee at Glasgow Royal 
Infirmary.  
Methods
Patients underwent ultrasound assessment of their hepatic arterial and portal venous 
blood flow at daily intervals, where clinically practical, during their intensive care 
stay.  Hepatic arterial, portal venous blood and total liver flow was assessed as 
previously described in Chapter 2.
Admission demographics including APACHE-II score and predicted mortality were 
recorded.  Serum C-reactive protein and the degree of organ support and was assessed 
daily.  ITU and hospital outcome data was collected.95
Statistics
Comparisons of baseline characteristics of patient groups were performed by Chi-
square or Mann-Whitney U test as appropriate.  Paired comparisons between different 
study days was performed by Wilcoxon signed rank test.  Analysis was performed 
using SPSS software (SPSS Inc., Chicago, IL, USA).96
5.3  Results
Baseline measurements of liver blood flow, organ support and the systemic 
inflammatory response in control and critically-ill patients are shown in Table 2.  
Thirty-one intensive care patients were recruited with a total of 202 measurements of 
hepatic arterial and portal venous blood flow performed.  Control and critically-ill 
groups were similar in terms of age and sex.  The median APACHE II score on 
admission was 21 and predicted survival was 35%.  In the critically-ill patient group 
hepatic arterial blood flow (p<0.05) and C-reactive protein concentrations (p<0.001) 
were significant higher compared with controls.  In contrast, portal venous blood flow 
was similar to controls (p=0.147).  The median C-reactive protein concentration in the 
critically-ill group was 103mg/l.
When liver blood flow measurements at the peak systemic inflammatory response in 
the critically-ill group were compared with control group (Table 3), there was, in 
addition to an increase in hepatic arterial blood flow (p<0.001), an increase in total 
liver blood flow (p<0.01).  The median C-reactive protein concentration at the peak of 
the inflammatory response in the critically-ill group was 168mg/l.
Longitudinal measurements of liver blood flow, organ support and the systemic 
inflammatory response in critically-ill patients are shown in Tables 4a and 4b.  Due to 
the nature of the changing critically-ill population studied (patients entered the study 
at different times due to clinical imperative and left the study at different times due to 
death or discharge from the intensive care) comparisons were carried out between the 
average measurements in one 24 hour period, compared to the next 24 hour period for 
days 0-5 (Table 4a).  For the subsequent measurements up to day 13, comparisons 97
were carried out between the average measurements in one 48 hour period, compared 
to the next 48 hour period (Table 4b).
In the first five 24 hour periods (Table 4a) there were no significant changes in liver 
blood flows.  In contrast, C-reactive protein was significantly increased from day 0 to 
day 1 and fell significantly from day 3 to day 4.  
In the second four 48hour periods (Table 4b) there were increases in hepatic arterial 
(p<0.05), portal venous (p<0.05) and total liver blood flows (p<0.05) between days 
10/11 and 12/ 13.
All scans performed in intensive care patients (n=202) were used to assess for 
correlation between inflammatory status and blood flows (Figures 1-3).  There was a 
trend towards a positive association between hepatic arterial blood flow and C-
reactive protein (rs= 0.074, Figure 1a).  In contrast, there was no association between 
portal venous blood flow and C-reactive protein (rs>0.001, Figure 2a), or C-reactive 
protein and total liver blood flow (rs= 0.013, Figure 3)98
5.4  Discussion
In the present study hepatic arterial flow, on admission, was higher in critically-ill 
patients compared with age and sex matched controls.  Furthermore, it was shown 
that, at the peak of their systemic inflammatory response, there was an increase in 
hepatic arterial blood flow in patients with critical illness in addition to the increase in 
total liver blood previously reported (9;79;120-122).  With respect to the longitudinal 
measurements carried out in the patients with critical illness the results were less clear 
cut since, following admission, there were fluctuations in both blood flow 
measurements and the systemic inflammatory response.  Nevertheless, including all 
blood flow and C-reactive protein values in the first two weeks of study (n=140) there 
was a trend towards a significant positive association between hepatic arterial blood 
flow and C-reactive protein but not portal venous blood flow and C-reactive protein.  
Therefore, the results of the present study are consistent with the concept that the 
systemic inflammatory response is an important mediator of hepatic arterial and total 
liver blood flow in patients with critical illness.  
In the introductory chapter (Chapter 1) we discussed both the intrinsic or extrinsic 
factors controlling liver blood flow.  However, in the critically-ill patient with the loss 
of homeostasis it is likely that a number of other factors will impact on the 
components of liver blood flow.  For example, there is an additional metabolic 
demand placed on the liver as protein synthesis, cytokine production and 
gluconeogenesis are all stimulated as part of the systemic inflammatory response.  
Also, there is likely to be increased metabolic activity in the liver resulting in 
accumulation of metabolic products (hydrogen ions, ADP, ATP) and these are 
potently vasoactive causing local vasodilatation and increased blood flow (100;101).  99
Extrinsic factors such as endogenous and exogenous catecholamines affect liver blood 
flow, high levels of adrenaline leading to the fight or flight effect and diverting blood 
away from the gastrointestinal tract to the more immediately important organs, low 
levels causing vasodilatation and increased liver blood flow (11).  Increases in liver 
blood flow are also associated with increased gastro-intestinal intraluminal osmolality 
(102;108) and therefore it is of interest that all the critically ill patients were fed from 
the day of admission to ITU.
Therefore, due to the complexity of factors that may alter liver blood flow in patients 
with critical illness it is not possible to attribute the blood flow changes to any 
individual factor with confidence.  However, it of interest that there was a direct 
association of hepatic arterial, but not portal venous, blood flow and the systemic 
inflammatory response, as evidenced by elevated C-reactive protein concentrations.  
Moreover, the results of the present study are consistent with previous two Chapters 
and implicate the systemic inflammatory response as a driver of hepatic arterial blood 
flow in health and disease.100
Table 1a.  Admission characteristics of study patients
Reason for admission Age Sex APACHE II Predicted 
mortality
1 Post op, small bowel obstruction 29 F 10 3.3
2 Post op, perforated colon 78 M 28 77.5
3 Post op, small bowel obstruction 53 M 11 5.0
4 Post op, elective AAA, pneumonia 73 F 15 21.0
5 Post op, elective AAA 65 M 13 5.0
6 Post op, elective facial cancer 
surgery 69 M 16 11.2
7 Post op, emergency AAA, renal 
failure 64 M 28 78.6
8 Sepsis, asystolic arrest 77 M 31 73.3
9 9% burns- face and hands 46 M 7 3.3
10 Post op, emergency AAA 70 F 21 23.8
11 Post op, necrotising fasciitis 31 F 14 26.8
12 Aspiration pneumonia 49 F 13 16.5
13 Post op, emergency AAA, 
respiratory and renal falure 77 M 21 38.9
14 Post op, congenital neck deformity 21 M 10 5.0
15 Pancreatitis, respiratory failure 75 F 26 50.7
16 COPD and pneumonia 66 F 30 49.3
17 Post op, perforated colon 37 M 19 48.0
18 Post op, small bowel obstruction 55 F 18 28.9
19 Post op, drainage subdural 
haematoma 67 M 26 35.2
20 Left ventricular failure and arrest 65 F 25 62.9
21 Post op, elective AAA 84 M 21 57.0
22 Post op, pulmonary lobectomy and 
MI post operatively 64 M 20 30.0
23 Post op, submandibular abscess 43 M 27 38.6
24 Pancreatitis 29 M 26 68.6
25 Post op, large bowel obstruction 38 F 14 30.8
26 Post op, completion proctectomy, 
intra op. bleed 77 F 13 16.4
27 Pancreatitis 75 F 27 71.6
28 Post op, bleeding duodenal ulcer 82 F 22 42.1
29 Post op, bleeding duodenal ulcer 71 M 34 80.7
30 Post op, osteosarcoma mandible 30 M 13 16.5
31 Post op, redo vascular surgery (ax bi 
fem graft) 72 M 33 78.6101
Table 1b Summary of Admissions by Type
Age (yrs) Sex (M:F) APACHE II Predicted 
mortality (%)
Surgical
(n=27)
65 (21-84) 17: 10 10 (7-34) 30.8 
(3.3-80.7)
Medical
(n=4)
66 (49-77) 1: 3 27.5 (13-31) 56.1
(16.5-73.3)
Values- median (range)Table 2.  Baseline measurements of liver blood flow, organ support and the systemic inflammatory response in control and critically-ill patients
Controls,
(n=18)
Critically-ill
(n=31)
P-value
Age 72 (36-87) 65 (21-85) 0.237
Sex (M:F) 9:9 18:13 0.584 
APACHE II 21 (7-34)
Organs supported (n) 1 (0-3)
HABF (ml/min) 366 (98-689) 542 (130-1472) 0.029
PVBF (ml/min) 1361 (616-2572) 1176 (587-2590) 0.820
TLBF (ml/min) 1759 (714-3141) 1996 (730-4040) 0.213
C-Reactive Protein (mg/l) <6 (<6-8) 103 (22-390) <0.001
Values- median (range)
HABF- hepatic arterial blood flow, PVBF- portal venous blood flow, TLBF- total liver blood flow.103
Table 3.  Measurements of liver blood flow, organ support at the peak systemic inflammatory response in critically-ill patients
Controls,
n=18
ITU patients,
n=31
P
Age 72 (36-87) 65 (21-85) 0.237
Sex (M:F) 9:9 18:13 0.584
Organs supported (n) 1 (0-3)
HABF (ml/min) 366 (98-689) 648 (202-1472) <0.001
PVBF (ml/min) 1361 (616-2572) 1494 (644-2588) 0.147
TLBF (ml/min) 1759 (714-3141) 2308 (1102-4039) 0.003
C-Reactive Protein (mg/l) <6 (<6-8) 168 (45-390) <0.001
Values- median (range)
HABF- hepatic arterial blood flow, PVBF- portal venous blood flow, TLBF- total liver blood flow.104
Table 4a.  Longitudinal measurements of liver blood flow, organ support and the systemic inflammatory response in critically-ill patients.
Day 0-1 Day 1-2 Day 2-3 Day 3-4 Day 4-5
N 7, 10 10, 12 12, 14 14, 17 17, 15
Pairs 6 6 7 12 10
Organs 
supported 
(mean n)
1 (0-3), 1 (0-3) 1 (0-3), 1 (0-3) 1 (1-3), 1 (1-3) 1 (1-3), 1 (1-3) 1 (1-3), 1 (1-2)
HABF 379 (282-1162),
562 (405-1472)
562 (405-1472),
575 (201-1432)
575 (201-1432),
638 (369-1436)
638 (369-1436),
500 (209-1219)
500 (209-1219),
647 (233-1301)
PVBF 1305 (798- 2099),
1386 (811-2568)
1386 (811-2568),
1141 (587-2590)
1141 (587-2590),
1145 (643-2097)
1145 (643-2097),
1445 (659-2158)
1445 (659-2158),
1746 (783-2493)
TLBF 2062 (1350- 2466),
2007 (1293- 4040)
2007 (1293- 4040),
1763 (1048- 3393)
1763 (1048- 3393),
1698 (1012- 3533)
1698 (1012- 3533),
1996 (981- 2880)
1996 (981- 2880),
2483 (1042-3794)
CRP (mg/l) 84 (22-390),
164 (22-267) *
164 (22-267),
173 (45-337)
173 (45-337),
129 (59- 292)
129 (59- 292),
107 (42-232) **
107 (42-232),
114 (24- 266)
Values- median (range)
HABF- hepatic arterial blood flow, PVBF- portal venous blood flow, TLBF- total liver blood flow CRP C-reactive protein, 
*p<0.05, **p<0.005105
Table 4b.  Longitudinal measurements of liver blood flow, organ support and the systemic inflammatory response in critically-ill patients.
Day 4/5 – 6/7 Day 6/7 – 8/9 Day 8/9 – 10/11 Day 10/11- 12/13
N 22, 10 10, 12 12, 11 11, 11
Pairs 8 7 8 6
Organs 
supported 
(mean n)
1 (1-2), 1 (1-2) 1 (1-2), 1 (0-2) 1 (0-2), 1 (0-2) 1 (0-2), 1 (0-2)
HABF 664 (209-1300),
573 (294-1015)
573 (294-1015),
591 (277-871)
591 (277-871),
465 (292-815)
465 (292-815),
659 (360-937) *
PVBF 1510 (752-2495),
1334 (889-1793)
1334 (889-1793),
1311 (691- 1966)
1311 (691- 1966),
1127 (720- 2153)
1127 (720- 2153),
1462 (1134- 2095) *
TLBF 2238 (1012- 3794),
2050 (1357- 2700)
2050 (1357- 2700),
1836 (1069- 2837)
1836 (1069- 2837),
1670 (1310- 2491)
1670 (1310- 2491),
2091 (1742- 3031) *
CRP 118 (36-266),
101 (55-214)
101 (55-214),
172 (36-231)
172 (36-231),
91 (13-264)
91 (13-264),
94 (41-218)
Values- median (range)
HABF- hepatic arterial blood flow, PVBF- portal venous blood flow, TLBF- total liver blood flow CRP C-reactive protein, 
* p<0.05Figure 1a.  Hepatic arterial blood flow and inflammation in all patients
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Figure 1a demonstrates hepatic arterial blood flow in ml/min (y-axis) against C-
Reactive Protein (x-axis) in all study patients.  Individual patients are coded in 
different colours and the overall line of best fit is displayed.107
Figure 1b.  Hepatic arterial blood flow and inflammation in survivors 
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Figure 1b demonstrates hepatic arterial blood flow in ml/min (y-axis) against C-
Reactive Protein (x-axis) in survivors.  Individual patients are coded in different 
colours and individual lines of best fit are displayed.108
Figure 1c.  Hepatic arterial blood flow and inflammation in non-survivors
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Figure 1c demonstrates hepatic arterial blood flow in ml/min (y-axis) against C-
Reactive Protein (x-axis) in non-survivors.  Individual patients are coded in different 
colours and individual lines of best fit are displayed.109
Figure 2a.  Portal Venous Blood Flow and inflammation in all patients
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Figure 2a demonstrates portal venous blood flow in ml/min (y-axis) against C-
Reactive Protein (x-axis) in all study patients.  Individual patients are coded in 
different colours and the overall line of best fit is displayed.110
Figure 2b.  Portal Venous Blood Flow and inflammation in survivors
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Figure 2b demonstrates portal venous blood flow in ml/min (y-axis) against C-
Reactive Protein (x-axis) in survivors.  Individual patients are coded in different 
colours and individual lines of best fit are displayed.111
Figure 2c.  Portal Venous Blood Flow and inflammation in non-survivors 
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Figure 2c demonstrates portal venous blood flow in ml/min (y-axis) against C-
Reactive Protein (x-axis) in non-survivors.  Individual patients are coded in different 
colours and individual lines of best fit are displayed.112
Figure 3  Total Liver Blood Flow and Inflammation in all patients
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Figure 3 demonstrates portal venous blood flow in ml/min (y-axis) against C-Reactive 
Protein (x-axis) in all study patients.  Individual patients are coded in different colours 
and the overall line of best fit is displayed.113
Chapter 6 :  Discussion and Conclusions114
Advances in ultrasound technology have allowed measurement of individual arteries 
trans-abdominally and therefore non-invasively.  This has mostly been applied in the 
oncological setting, where it is postulated that changes in blood flow are present when 
there are micrometastasis to the liver that are not detectable by other imaging.  Most 
studies that have been carried out to assess liver blood flow in the setting of systemic 
inflammation have assessed total liver blood flow and have not assessed the 
individual contribution of the hepatic arterial and portal venous circulations.  It is 
generally agreed across the literature that total liver blood flow is increased in 
systemic inflammation and the results of chapter 3 would corroborate this.  It would 
also appear that increase in hepatic arterial flow is responsible for this and the portal 
venous flow is unchanged.
Since this study was performed there have been advances in techniques to measure 
blood flow and further studies should take advantage of these to minimise intra-
observer error.  Blood flow through the liver is difficult to measure in the clinical 
setting.  In animals it is acceptable to cannulate the hepatic vein or place flow probes 
directly onto vessels operatively.  In patients there are almost no clinical indications 
for hepatic venous cannulation and as this is an invasive procedure with morbidity 
attached, therefore it is unlikely that studies in critically ill patients measuring total 
liver blood flow by the Fick principal will be repeated.  Magnetic Resonance Imaging 
(MRI) can provide the means of assessing liver perfusion however there are logistical 
difficulties of transferring ventilated patients to a MRI scanner where no metal is 
allowed in the room.  This leaves us with ultrasound as a non-invasive method of 
assessment of portal venous and hepatic arterial blood flow.  When trans-abdominal 
ultrasound was carried out there was found to be a variation of around 30% at 5 115
minute and 2 hour intervals where a stable mean arterial blood pressure was present.  
Endoscopic ultrasound allows almost direct contact with the portal vein and hepatic 
artery but justifying this in a study setting would be difficult.
Ultrasound contrast agents may help in assessing liver blood flow non-invasively.  
These small (typically 3 µm indiameter) gas filled bubbles are given intravenously 
and vibrate in the presence of an ultrasound signal, enhancing reflection.  The recent 
developments in ultrasound contrast and software to interpret scans using this agent 
has allowed measurement of perfusion of the liver and may allow more accurate and 
repeatable measurement of portal venous and hepatic arterial flow.  One advantage of 
this would be that the vessels themselves need not be imaged and a sonograph with an 
easily accessible area of liver could be re-imaged.  This would make the scanning
much easier and negate the effect of feed/gas in the duodenum which often leads to 
sub-optimal views of the vessels.  The image would be recorded as the contrast 
bubbles perfused the liver and the computer software would generate perfusion graphs 
of the liver with a hepatic arterial and portal venous phase. Changes inintensity (or 
loudness) of a spectral Doppler signal are proportionalto microbubble concentration.
The timing of liver blood flow changes has not been satisfactorily explained.  Infusion 
of a pro-inflammatory cytokine in healthy volunteers provokes an increase in liver 
blood flow that occurs within 4 hours.  The single study that has assessed liver blood 
flow using colour Doppler/duplex ultrasound in the intensive care setting had reported 
an increased hepatic arterial blood flow at 5 hours after the onset of illness, however 
this returned to normal after 24 hours.  The question ‘What changes in hepatic arterial 
and portal venous flow occur at onset of inflammation and what are the timings of116
these changes?’ is not answered by these studies.  Infusion of a pro-inflammatory 
cytokine in healthy volunteers is a very artificial situation and we have discussed in 
the introduction that, as well as pro-inflammatory cytokines, an appropriate hormonal 
environment is also necessary for the physiological changes of systemic inflammation 
to manifest themselves.  Similarly the onset of systemic inflammation is very difficult 
to define and the study that measured hepatic arterial and portal venous flow 5 hours 
after admission to intensive care provides no information on how onset of systemic 
inflammation was derived.  To assess the timing of changes in chapter 4 we chose an 
inflammatory stimulus that was repeatable and controlled.  Classically the ‘fight or 
flight’ response, which is mediated by the adrenal medullary hormones, serves to 
divert blood away from the non-essential organs in favour of the heart, brain and 
kidneys.
Further work in this field is required to discover the mediator of changes in liver 
blood flow.  It is understood that increased concentrations of metabolic products at a 
cellular level, elevated concentrations of circulating hormones and cytokines and 
increased cardiac output all cause increased liver blood flow and it is conceivable that 
any of these factors could be the cause of increased blood flow in systemic 
inflammation.  Infusion of pro-inflammatory agents will stimulate the liver to produce 
acute phase proteins and glucose which will increase the concentration of metabolic 
products in the liver.  Demonstration of an increase in liver blood flow in this 
situation will not indicate if blood flow is a direct effect of the pro-inflammatory 
cytokine or its effect on the liver.  Hormones have been shown to have a direct effect 
on the splanchnic arterioles, exhibiting both alpha and beta adrenoceptor effects.  An 
appropriate counter regulatory hormone environment will potentiate the effect of pro-117
inflammatory cytokines on the liver and induce an acute phase response.  Direct 
hormonal effects will be immediate and we would expect the effects of increased 
metabolism to be later.  The acute phase proteins begin to appear at 6 hours post 
injury.  Cortisol is increased maximally at 6 hours and white blood cells maximally at 
8-10 hours.  The peak concentration of C-Reactive protein is not seen until 48 hours.  
Our demonstration of increased hepatic arterial blood flow peaking at 4 hours post-
operatively would not be supported by increased metabolic rate in the liver which 
goes on for at least 48 hours post injury.  Nitric oxide is another potential mediator 
and while there is strong evidence in rats and mice that inhibition of nitric oxide 
synthase does not give the typical increase in liver blood flow seen after 
administration of lipopolysacharide or other inflammatory stimuli, this may not be 
simply extrapolated to humans.  Nitric oxide and its effect on the liver have been 
studied in the cirrhotic liver and there is evidence that decreased nitric oxide is a 
factor in the increased vascular resistance and portal hypertension seen in cirrhotic 
liver disease.  This has not been studied in critical illness.  The changes that we have 
seen in the present study would more likely be hormonal or cytokine (or both) related 
and this study could be repeated with sampling of blood for assessment of these 
mediators.
The final study in the thesis demonstrated an increase in hepatic arterial flow and total 
liver blood flow in critically ill patients compared with controls.  This concurs with 
previous studies and adds to the literature that these changes are mediated mainly by 
the hepatic artery.  Serial blood flow measurements did not give any significant 
findings but there appeared to be a tendency to increased hepatic arterial flow with 
increased systemic inflammation.118
We have shown that ultrasound assessment of hepatic arterial blood flow and 
portal venous blood flow can be carried out in the intensive care setting and that our 
results correspond to previously published work.  The next step would be finding a 
clinical  use  for  this  test.    The  most  likely  use  for  this  would  be  as  a  prognostic 
indicator.    In  the  small  numbers  that  we  studies  we  were  not  able  to  show  any 
differences  in  the  survivors  and  non-survivors.    An  impression  of  serial  results 
obtained was that the patients that survived had less variance in their blood flow with 
the corresponding level of systemic inflammation compared with those who died.  A 
much larger study would be needed to statistically demonstrate such a relationship.  It 
would also be useful to measure the changes in the components of liver blood flow 
before and after an intervention that is known to modulate the systemic inflammatory 
response  and  influence  outcome  (for  example  activated  protein  c).    Further  such 
investigations of the components of liver blood flow are required to understand better 
how the liver responds to inflammatory challenges and how such responses might 
influence survival.119
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Appendix 1 Chapter 3 patients
Table A
Control subjects
No
M0
F1 Age TLBF HAF PVF HATAM PVTAM HA XSA PVXSA
1 1 57 1467 368 1098 19.8 16.2 0.31 1.13
2 0 77 1246 324 922 18.0 12.6 0.30 1.22
3 0 36 1391 322 1069 23.3 16.2 0.23 1.10
4 1 30 1715 333 1382 19.8 18.0 0.28 1.28
5 1 58 714 98 616 10.2 10.8 0.16 0.95
6 0 57 916 193 722 29.3 10.2 0.11 1.18
7 0 80 3141 569 2572 31.6 26.3 0.30 1.63
8 1 79 1831 302 1528 18.0 12.8 0.28 1.99
9 1 60 1103 233 869 14.4 9.0 0.27 1.61
10 0 77 1804 397 1406 18.4 12.6 0.36 1.86
11 0 58 1381 436 946 22.0 14.2 0.33 1.11
12 0 75 1911 572 1339 25.1 15.5 0.38 1.44
13 0 84 2050 363 1687 23.3 25.1 0.26 1.12
14 1 80 1700 391 1309 18.1 15.7 0.36 1.39
15 1 71 1957 556 1401 33.1 17.3 0.28 1.35
16 1 70 2309 689 1620 35.9 18.0 0.32 1.50
17 0 60 1892 458 1434 21.2 14.4 0.36 1.66
18 1 72 2503 403 2101 30.5 28.7 0.22 1.22
M Male F Female; TLBF Total liver blood flow (ml/min); HAF Hepatic artery flow 
volume (ml/min); PVF Portal venous flow volume (ml/min); HATAM Hepatic artery 
time-averaged velocity (cm/s); HAXSA Hepatic artery cross sectional area (cm
2); 
PVTAM Portal vein time-averaged velocity (cm/s); PVXSA Portal cross sectional 
area (cm
2).135
Table B
Non-small cell lung cancers
No
M0
F1 Age TLBF HAF PVF HATAM PVTAM HA XSA PVXSA
1 0 56 2904 730 2174 32.00 30.20 0.38 1.20
2 1 68 1786 467 1319 25.10 19.80 0.31 1.11
3 0 54 2068 677 1391 30.50 16.80 0.37 1.38
4 0 69 2031 680 1351 32.40 16.20 0.35 1.39
5 0 85 1769 379 1390 30.10 19.80 0.21 1.17
6 1 60 1812 650 1162 25.80 11.60 0.42 1.67
7 0 80 2939 1115 1824 41.30 18.20 0.45 1.67
8 0 69 969 295 674 20.50 10.90 0.24 1.03
9 0 79 1840 742 1097 39.90 15.50 0.31 1.18
10 0 49 1002 339 663 21.70 9.70 0.26 1.14
M Male F Female; TLBF Total liver blood flow (ml/min); HAF Hepatic artery flow 
volume (ml/min); PVF Portal venous flow volume (ml/min); HATAM Hepatic artery 
time-averaged velocity (cm/s); HAXSA Hepatic artery cross sectional area (cm
2); 
PVTAM Portal vein time-averaged velocity (cm/s); PVXSA Portal cross sectional 
area (cm
2).136
Table C
Acute alcohol hepatitics
No
M0
F1 Age TLBF HAF PVF HATAM PVTAM HA XSA PVXSA
1 0 46 1166 242 924 16.8 14.4 0.24 1.07
2 1 55 2595 1138 1457 47.4 13.2 0.40 1.84
3 0 50 2264 941 1323 54.1 13.2 0.29 1.67
4 0 51 1392 491 900 21.0 8.2 0.39 1.83
5 0 38 1093 405 688 30.7 9.8 0.22 1.17
6 0 45 2076 1050 1026 38.9 12.3 0.45 1.39
7 0 53 1470 738 732 29.3 8.3 0.42 1.47
M Male F Female; TLBF Total liver blood flow (ml/min); HAF Hepatic artery flow 
volume (ml/min); PVF Portal venous flow volume (ml/min); HATAM Hepatic artery 
time-averaged velocity (cm/s); HAXSA Hepatic artery cross sectional area (cm
2); 
PVTAM Portal vein time-averaged velocity (cm/s); PVXSA Portal cross sectional 
area (cm
2).137
Appendix 2 Chapter 4 patients
Table A
Patients
Patient M0 f1 Age RA/OA NSAID Steroid Immunosuppresor Op Date Joint
1 0 80 OA No no No 09/07/2002 Knee
2 1 79 OA ibuprofen no No 10/09/2002 Knee
3 1 63 RA diclofenac pred 3mg sulphasalazine 10/09/2002 Hip
4 1 73 RA naproxen no Gold 17/09/2002 Rev. knee
5 1 66 RA No no No 17/09/2002 Knee
6 1 60 OA vioxx no No 17/09/2002 Knee
7 0 77 OA celebrex no No 17/09/2002 Knee
8 1 36 RA celebrex pred 7.5mg Methotrexate 24/09/2002 Knee
9 0 76 OA No no No 24/09/2002 Knee
10 0 75 OA No no No 08/04/2003 Knee
11 0 58 OA vioxx no No 08/04/2003 Knee
12 0 84 OA No no No 15/04/2003 Hip
13 0 80 OA No no No 29/04/2003 Rev. knee
14 1 71 OA No no No 29/04/2003 Knee
15 1 63 OA ibuprofen no No 10/06/2003 Knee
16 1 74 OA No no No 10/06/2003 Knee
17 1 70 OA naproxen no No 10/06/2003 Hip
18 0 60 OA N no No 10/06/2003 Knee
19 1 72 OA aspirin no No 29/07/2003 Knee
20 1 70 OA No no No 29/07/2003 Knee
M male; F female; RA rheumatoid arthritis; OA osteoarthritis; NSAID non-steroidal 
anti-inflammatory drug138
Table B
Blood flow measurements
Patient Date  Time HATAM HAXSA PVTAM PVXSA HAF PVF TLBF
1 08/07/2002 17:00 31.60 0.30 26.30 1.63 569 2572 3141
1 09/07/2002 12:30 23.00 0.31 7.60 1.49 428 679 1107
1 09/07/2002 14:30 29.90 0.33 10.50 1.72 592 1084 1676
1 09/07/2002 16:30 29.90 0.35 21.10 1.42 628 1798 2426
1 09/07/2002 18:30 23.30 0.30 16.10 1.57 419 1517 1936
1 10/07/2002 10:00 25.20 0.31 12.20 1.86 469 1362 1830
1 10/07/2002 17:00 21.60 0.28 12.40 1.48 363 1101 1464
1 11/07/2002 10:00 23.60 0.33 8.70 1.68 467 877 1344
2 09/09/2002 16:30 18.00 0.28 12.80 1.99 302 1528 1831
2 10/09/2002 16:00 34.40 0.27 14.40 1.63 557 1408 1966
2 10/09/2002 18:00 25.50 0.31 15.50 1.53 474 1423 1897
2 10/09/2002 20:00 21.50 0.30 12.60 1.64 387 1240 1627
2 10/09/2002 22:00 19.80 0.34 10.80 1.57 404 1017 1421
2 11/09/2002 09:00 21.50 0.27 16.60 1.43 348 1424 1773
2 11/09/2002 18:00 19.80 0.28 8.70 1.67 333 872 1204
3 09/09/2002 16:45 36.10 0.22 16.60 1.44 477 1434 1911
3 10/09/2002 12:20 26.50 0.29 12.00 1.36 461 979 1440
3 10/09/2002 14:20 36.10 0.29 15.00 1.39 628 1251 1879
3 10/09/2002 16:20 42.80 0.35 15.00 1.31 899 1179 2078
3 10/09/2002 18:20 42.10 0.33 24.10 1.35 834 1952 2786
3 11/09/2002 09:15 32.20 0.29 16.40 1.48 560 1456 2017
3 11/09/2002 18:00 21.50 0.29 23.30 1.39 374 1943 2317
4 16/09/2002 15:45 21.50 0.28 14.40 1.79 361 1547 1908
4 17/09/2002 12:00 16.70 0.35 15.00 1.57 351 1413 1764
4 17/09/2002 14:00 26.90 0.39 18.00 1.23 629 1328 1958
4 17/09/2002 16:00 36.10 0.33 23.30 1.19 715 1664 2378
4 17/09/2002 18:00 16.20 0.28 18.00 1.47 272 1588 1860
4 18/09/2002 10:00 28.70 0.40 16.20 1.79 689 1740 2429
4 18/09/2002 18:00 16.20 0.34 23.30 1.31 330 1831 2162
5 16/09/2002 16:00 19.80 0.27 16.20 1.80 321 1750 2070
5 17/09/2002 17:00 14.40 0.38 14.40 1.40 328 1210 1538
5 17/09/2002 19:00 23.30 0.37 12.60 1.43 517 1081 1598
5 17/09/2002 21:00 23.30 0.33 12.60 1.65 461 1247 1709
5 18/09/2002 10:00 18.00 0.36 12.60 1.66 389 1255 1644
5 18/09/2002 18:00 23.30 0.33 18.00 1.68 461 1814 2276
6 16/09/2002 16:10 14.40 0.27 9.00 1.61 233 869 1103
6 17/09/2002 11:45 12.60 0.36 9.00 1.45 272 783 1055
6 17/09/2002 13:45 19.80 0.31 10.80 1.56 368 1011 1379
6 17/09/2002 15:45 35.90 0.34 7.20 1.28 732 553 1285
6 17/09/2002 17:45 18.00 0.31 14.40 1.38 335 1192 1527
6 18/09/2002 10:00 16.20 0.26 10.80 1.25 253 810 1063
6 18/09/2002 18:00 14.40 0.30 12.60 1.70 259 1285 1544
7 16/09/2002 16:30 18.40 0.36 12.60 1.86 397 1406 1804
7 17/09/2002 15:30 12.50 0.35 5.20 1.60 263 499 762
7 17/09/2002 17:30 12.50 0.35 7.20 1.64 263 708 971
7 17/09/2002 19:30 16.40 0.28 10.40 1.52 276 948 1224
7 17/09/2002 21:30 14.40 0.30 9.00 1.50 259 810 1069
7 18/09/2002 10:00 18.00 0.30 9.00 1.58 324 853 1177
7 18/09/2002 18:00 34.10 0.35 16.20 1.90 716 1847 2563
8 23/09/2002 16:00 23.60 0.26 14.40 1.47 368 1270 1638139
8 24/09/2002 16:30 25.10 0.27 9.00 1.58 407 853 1260
8 24/09/2002 18:30 21.50 0.30 9.00 1.38 387 745 1132
8 24/09/2002 20:30 23.30 0.30 10.80 1.58 419 1024 1443
8 24/09/2002 22:30 18.00 0.32 10.30 1.54 346 952 1297
8 25/09/2002 10:00 21.50 0.29 16.60 1.65 374 1643 2018
8 25/09/2002 18:00 19.80 0.29 14.40 1.75 345 1512 1857
9 23/09/2002 16:00 18.00 0.27 12.60 1.24 292 937 1229
9 24/09/2002 confused
10 07/04/2003 15:45 25.10 0.38 15.50 1.44 572 1339 1911
10 08/04/2002 11:00 30.50 0.35 16.20 1.26 641 1225 1865
10 08/04/2002 13:00 19.80 0.39 16.20 1.33 463 1293 1756
10 08/04/2002 15:00 18.00 0.35 12.60 1.31 378 990 1368
10 08/04/2002 17:00 20.40 0.36 18.00 1.34 441 1447 1888
10 09/04/2002 09:00 25.10 0.36 18.00 1.40 542 1512 2054
10 09/04/2003 18:00 25.10 0.39 18.70 1.38 587 1548 2136
11 07/04/2003 16:00 22.00 0.33 14.20 1.11 436 946 1381
11 08/04/2002 arrest
12 14/04/2003 16:00 23.30 0.26 25.10 1.12 363 1687 2050
12 15/04/2003 16:00 25.10 0.30 16.30 1.23 452 1203 1655
13 28/04/2003 16:00 18.10 0.36 15.70 1.39 391 1309 1700
14 28/04/2003 16:00 33.10 0.28 17.30 1.35 556 1401 1957
14 29/04/2003 11:00 35.90 0.25 15.50 1.34 539 1246 1785
14 29/04/2003 13:00 32.30 0.25 18.00 1.41 485 1523 2007
14 29/04/2003 15:00 38.90 0.30 14.40 1.34 700 1153 1854
14 29/04/2003 17:00 21.50 0.30 15.50 1.40 387 1302 1689
14 30/04/2003 10:00 26.70 0.32 12.00 1.33 513 958 1470
14 30/04/2003 17:00 30.30 0.30 14.40 1.35 545 1166 1712
15 09/06/2003 18:00 20.10 0.35 16.20 1.19 422 1157 1579
15 10/06/2003 11:00 23.30 0.33 16.60 1.15 461 1145 1607
16 09/06/2003 18:00 26.90 0.33 16.20 1.20 533 1166 1699
16 10/06/2003 13:00 30.90 0.34 12.60 1.28 630 968 1598
17 09/06/2003 18:00 35.90 0.32 18.00 1.50 689 1620 2309
17 10/06/2003 11:00 21.10 0.34 5.20 1.45 430 452 883
17 11/06/2003 13:00 23.30 0.34 12.20 1.48 475 1083 1559
18 09/06/2003 18:00 21.20 0.36 14.40 1.66 458 1434 1892
18 10/06/2003 13:00 18.00 0.40 9.20 1.59 432 878 1310
18 10/06/2003 15:00 24.40 0.37 12.60 1.60 542 1210 1751
19 28/07/2003 16:00 30.50 0.22 28.70 1.22 403 2101 2503
19 29/07/2003 11:00 27.70 0.25 19.80 1.15 416 1366 1782
19 29/07/2003 13:00 25.10 0.24 18.00 1.16 361 1253 1614
19 29/07/2003 15:00 30.90 0.25 18.00 1.20 464 1296 1760
19 29/07/2003 17:00 31.80 0.24 17.10 1.19 458 1221 1679
19 30/07/2003 10:00 32.00 0.24 24.60 1.20 461 1771 2232
20 28/07/2003 16:00 25.40 0.41 28.10 1.66 625 2799 3424
20 29/07/2003 13:00 22.20 0.38 9.80 1.47 506 864 1371
20 29/07/2003 15:00 27.80 0.40 18.00 1.44 667 1555 2222
20 29/07/2003 17:00 26.60 0.40 25.10 1.45 638 2184 2822
20 29/07/2003 19:00 22.20 0.39 19.90 1.49 519 1779 2299
20 30/07/2003 11:00 28.00 0.38 17.40 1.50 638 1566 2204
TLBF Total liver blood flow (ml/min); HAF Hepatic artery flow volume (ml/min); 
PVF Portal venous flow volume (ml/min); HATAM Hepatic artery time-averaged 
velocity (cm/s); HAXSA Hepatic artery cross sectional area (cm
2); PVTAM Portal 
vein time-averaged velocity (cm/s); PVXSA Portal cross sectional area (cm
2).140Appendix 3  Chapter 5 patients
Patient 1
Age 29 years
Sex Female
Reason for admission post op, abdomen
APACHE II 10
Predicted mortality 3.3%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
1 0 16/11/2001 66 1087 1127 2214
1 1 17/11/2001 131 774 2484 3261142
Patient 2
Age 78 years
Sex Male
Reason for admission post op, abdomen
APACHE II 28
Predicted mortality 77.5%
Outcome death
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
2 0 17/11/2001 71 12 8 y y y
2 1 18/11/2001 59 9 11 y y y
2 2 19/11/2001 110 13 15 543 587 1130 y y y
2 3 20/11/2001 81 11 10 479 900 1379 y y
2 4 21/11/2001 75 8 12 227 777 1004 y y y
2 5 22/11/2001 83 8 14 421 1062 1483 y y y
2 6 23/11/2001 128 12 15 871 821 1692 y y y
2 7 24/11/2001 144 14 14 875 986 1861 y y y
2 8 25/11/2001 138 16 12 605 1213 1814 y y
2 9 26/11/2001 94 15 10 454 1148 1602 y y
2 10 27/11/2001 88 17 10 810 1328 2134 y y
2 11 28/11/2001 72 18 468 925 1389 y y
2 12 29/11/2001 88 19 745 1170 1915 y y
2 13 30/11/2001 75 18 y y
2 14 01/12/2001 59 7 y y
2 15 02/12/2001 54 6 y y
2 16 03/12/2001 62 20 12 y y y
2 17 04/12/2001 153 13 y y y
2 18 05/12/2001 188 23 10 y y y
2 19 06/12/2001 158 y y y143
Patient 3
Age 53 years
Sex Male
Reason for admission post op, abdomen
APACHE II 11
Predicted mortality 5.0%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
3 0 04/12/2001 73 378 1076 1454
3 1 05/12/2001 109 454 1209 1663
3 2 06/12/2001
3 3 07/12/2001
3 4 08/12/2001 175 500 1339 1839144
Patient 4
Age 73 years
Sex Female
Reason for admission post op, vascular
APACHE II 15
Predicted mortality 21.0%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
4 0 01/02/2002 151 22 9.5 y y
4 1 02/02/2002 159 5.1 y y
4 2 03/02/2002 177 18 7.4 y y
4 3 04/02/2002 149 19 6.2 y y
4 4 05/02/2002 112 21 6.3 y y
4 5 06/02/2002 91 23 8.8 y y
4 6 07/02/2002 75 22 10.9 y y
4 7 08/02/2002 53 22 11.9 y y
4 8 09/02/2002 47 22 14.4 y y
4 9 10/02/2002 52 24 12.8 y y
4 10 11/02/2002 36 22 11.6 y y
4 11 12/02/2002 58 42 10.2 y y
4 12 13/02/2002 84 25 9 y y
4 13 14/02/2002 80 26 10.4 y y
4 14 15/02/2002 53 9.1 292 867 1159 y y
4 15 16/02/2002 51 25 7.3 392 1361 1753 y y
4 16 17/02/2002 46 7 335 1037 1371 y y
4 17 18/02/2002 40 27 7.5 378 1555 1933 y y
4 18 19/02/2002 36 6.9 356 1501 1857
4 19 20/02/2002 55 29 10.1145
Patient 5
Age 65 years
Sex Male
Reason for admission post op, vascular
APACHE II 13
Predicted mortality 5.0%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
5 0 16/2/2002 90 27 8.8 378 1684 2062
5 1 17/2/2002 207 27 11.1 558 914 1472
5 2 18/2/2002 220 26 9.5 605 1735 2340146
Patient 6
Age 69 years
Sex Male
Reason for admission post op, plastic surgery
APACHE II 16
Predicted mortality 11.2%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
6 0 13/12/2001 208 26 14.9 y
6 1 14/12/2001 166 20 11 y y
6 2 15/12/2001 188 12.3 y y
6 3 16/12/2001 196 14 756 1724 2480 y y
6 4 17/12/2001 164 18 11.1 813 1908 2725 y y
6 5 18/12/2001 214 13.2 903 2113 3016 y y
6 6 19/12/2001 22 16.1 587 1792 2383 y y
6 7 20/12/2001 211 19 17.5 y y
6 8 21/12/2001 199 17 17 y y y
6 9 22/12/2001 230 15 18 y y y
6 10 23/12/2001 243 18.7 292 2152 2444 y y y
6 11 24/12/2001 211 18 14.6 y y y
6 12 25/12/2001 197 13.1 y y y
6 13 26/12/2001 203 20 10.9 y y y
6 14 27/12/2001 224 16.2 511 2332 2847 y y
6 15 28/12/2001 201 23 20.6 y y
6 16 29/12/2001 198 14.5 y y
6 17 30/12/2001 169 13.7 511 2376 2887 y y
6 18 31/12/2001 132 19 13.9 396 1591 1987 y y
6 19 01/01/2002 139 21 16.6 y y
6 20 02/01/2002 180 19 18.5 454 1890 2340 y y147
6 21 03/01/2002 179 19.5 421 1807 2228 y y
6 22 04/01/2002 162 18 17.5 y y
6 23 05/01/2002 142 18 16.5 y y
6 24 06/01/2002 124 16 y y
6 25 07/01/2002 104 19 17 y y
6 26 08/01/2002 81 16.5 y y
6 27 09/01/2002 83 20 19 y y
6 28 10/01/2002 94 21 14.8 y y
6 29 11/01/2002 69 24 13.8 y y
6 30 12/01/2002 60 13.4 y y
6 31 13/01/2002 50 24 15.2 y y
6 32 14/01/2002 45 23 13.7 392 1818 2210 y y
6 33 15/01/2002 66 13.7 270 2106 2376 y y
6 34 16/01/2002 48 24 11.3 450 2084 2534 y y
6 35 17/01/2002 57 14.5 263 1425 1688 y148
Patient 7
Age 64 years
Sex Male
Reason for admission post op, vascular
APACHE II 28
Predicted mortality 78.6%
Outcome death
Patient Day Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated PA 
Cath Inotrope Renal
7 0 16/02/2002 y y y y
7 1 17/02/2002 171 19 30.8 y y y y
7 2 18/02/2002 139 19 26.9 623 1177 1800 y y y
7 3 19/02/2002 103 25.7 763 1828 2591 y y y
7 4 20/02/2002 82 20 27.7 745 1415 2160 y y y
7 5 21/02/2002 20 27.1 y y y
7 6 22/02/2002 91 20 26.5 y y y
7 7 23/02/2002 107 20 26.7 y y y
7 8 24/02/2002 154 22 32.3 y y y
7 9 25/02/2002 163 19 30.4 y y y
7 10 26/02/2002 192 18 25.2 y y y
7 11 27/02/2002 196 20 22.5 y y y
7 12 28/02/2002 149 20 31.3 y y y y
7 13 01/03/2002 140 17 36.9 y y y
7 14 02/03/2002 21 39.1 y y y y
7 15 03/03/2002 17 56.6 y y y y149
Patient 8
Age 77 years
Sex Male
Reason for admission medical
APACHE II 31
Predicted mortality 73.3%
Outcome death
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
8 0 28/02/2002 69 18 9.4 y y
8 1 01/03/2002 162 17 10.7 y y
8 2 02/03/2002 195 19 13.8 y y y y
8 3 03/03/2002 168 19 13.6 y y y y
8 4 04/03/2002 112 18 11.7 y y y y
8 5 05/03/2002 97 19 13.3 y y y
8 6 06/03/2002 74 19 10.4 y y y
8 7 07/03/2002 83 19 y y y
8 8 08/03/2002 95 18 9.4 y y y y
8 9 09/03/2002 94 17 9.3 y y y y
8 10 10/03/2002 19 y y
8 11 11/03/2002 122 21 9.6 y y
8 12 12/03/2002 133 8.2 y y
8 13 13/03/2002 105 19 6.8 y y
8 14 14/03/2002 95 21 8.8 y y
8 15 15/03/2002 107 21 y y
8 16 16/03/2002 135 21 13.9 y y
8 17 17/03/2002 159 10.1 y y
8 18 18/03/2002 171 20 13.6 y y y
8 19 19/03/2002 154 15.5 641 1645 2286 y y
8 20 162 576 1591 2167150
8 20.5 20/03/2002 158 19 407 1487 1893 y y y
8 21 161 248 1263 1512
8 21.5 21/03/2002 143 20 22.9 450 1076 1526 y y y
8 22 136 281 846 1127
8 22.5 22/03/2002 104 21 19.4 248 1368 1616 y y y y
8 23 23/03/2002 95 20 12.6 y y y y
8 24 24/03/2002 46 20 11 y y y
8 25 25/03/2002 27 23 176 835 1011 y y y
8 26 21 184 759 943
8 26.5 26/03/2002 18 25 20.7 353 1451 1807 y y y
8 27 16 507 1609 2116
8 27.5 27/03/2002 25 24 24.2 443 900 1343 y y y
8 28 26 187 885 1073
8 28.5 28/03/2002 27 28 31.3 295 1206 1504 y y y
8 29 29/03/2002 15 26 30.9 y y y
8 30 30/03/2002 8 25 28.6 y y y
8 31 31/03/2002 6 24 31.3 y y y
8 32 01/04/2002 6 25 y y
8 33 02/04/2002 19 23 15.9 y y y
8 34 03/04/2002 12 24 24.3 y y
8 35 04/04/2002 19 28.9 y y
8 36 05/04/2002 122 24 y y
8 37 06/04/2002 135 25 22.8 y y y
8 38 07/04/2002 92 20.9 y y
8 39 08/04/2002 97 24 y y y
8 40 09/04/2002 98 561 1508 2070 y y
8 41 10/04/2002 95 22 y y
8 42 11/04/2002 78 968 1904 2872 y y
8 43 12/04/2002 73 27 y y151
Patient 9
Age 46 years
Sex Male
Reason for admission burns
APACHE II 7
Predicted mortality 3.3%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
9 0 14/03/2002 y y
9 1 15/03/2002 16 26 8.6 y y
9 2 16/03/2002 137 19 9.6 y y
9 3 17/03/2002 181 18 7.2 y y
9 4 18/03/2002 210 20 6.3 y y
9 5 19/03/2002 211 8.2 1299 2494 3794 y y
9 6 20/03/2002 195 19 7.8 673 1382 2055 y y
9 6.5 201 828 666 1494
9 7 21/03/2002 183 14.7 1141 705 1850 y y
9 7.5 188 392 1616 2012
9 8 22/03/2002 195 22 14.4 378 691 1069 y y
9 9 23/03/2002 136 21 13.2 y y
9 10 24/03/2002 140 23 17.6 y y
9 11 25/03/2002 157 18.2 461 1047 1508 y y
11.5 146 403 705 1109
9 12 26/03/2002 113 26 13.2 540 1375 1911 y y
9 12.5 75 918 907 1825
9 13 27/03/2002 56 26 11.6 579 1335 1915 y y
9 13.5 49 392 921 1314
9 14 28/03/2002 50 27 10.3 597 1400 1998 y y152
9 14.5 52 490 1454 1944
9 15 29/03/2002 69 26 10.1 y y
9 16 30/03/2002 72 27 9.4 y y153
Patient 10
Age 70 years
Sex Female
Reason for admission post op, vascular
APACHE II 21
Predicted mortality 23.8%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
10 0 01/04/2002 8 20 y y
10 1 02/04/2002 22 23 6 565 810 1375 y y
10 2 03/04/2002 182 24 16 810 1249 2059 y y
10 2.5 252 817 1742 2555
10 3 04/04/2002 253 18 680 1123 1803 y y
10 3.5 278 648 907 1555154
Patient 11
Age 31 years
Sex Female
Reason for admission post op, plastics
APACHE II 14
Predicted mortality 26.8%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
11 0 21/04/2002 7 y y y
11 1 22/04/2002 95 15 5 y y y
11 2 23/04/2002 68 15 7 623 1105 1728 y y
11 3 24/04/2002 59 16 7 655 921 1576 y y
11 4 25/04/2002 47 18 7 925 1954 2879 y y
11 5 26/04/2002 24 19 5 608 1792 2401155
Patient 12
Age 49 years
Sex Female
Reason for admission medical
APACHE II 13
Predicted mortality 16.5%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
12 0 21/04/2002 116 22 6.4 y y
12 1 22/04/2002 162 23 7.5 y y
12 2 23/04/2002 171 21 9.4 803 2588 3391 y y
2.5 23/04/2002 146 759 1980 2739
12 3 24/04/2002 124 17 8.4 407 1040 1447 y y
12 4 25/04/2002 81 14 10.5 529 1281 1807 y y
12 5 26/04/2002 72 15 13.5 767 1857 2627 y y
12 6 27/04/2002 49 18 21.4 y y
12 7 28/04/2002 52 19 19.6 y y
12 8 29/04/2002 42 20 18.8 623 1029 1648 y y
8.5 29/04/2002 37 903 1753 2656
12 9 30/04/2002 33 19 16.4 1159 3509 4668 y y
9.5 30/04/2003 31 792 1576 2368
12 10 01/05/2002 30 21 15.3 y y
12 11 02/05/2002 31 21 12.4 813 1487 2300 y y
12 12 03/05/2002 41 22 12.5 936 2095 3031 y y
12 13 04/05/2002 56 24 11.9 y y
12 14 05/05/2002 53 24 8.8 y y
12 15 06/05/2002 62 27 10.4 y y
12 16 07/05/2002 74 27 13.5 y y
12 17 08/05/2002 100 29 10.9 y y156
12 18 09/05/2002 87 29 10.5157
Patient 13
Age 77 years
Sex Male
Reason for admission post op, vascular
APACHE II 21
Predicted mortality 38.9%
Outcome death
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
13 0 07/06/2002 y y
13 1 08/06/2002 25 y y
13 2 09/06/2002 144 24 16 y y
13 3 10/06/2002 126 24 17 680 1400 2080 y y
13 4 11/06/2002 107 24 19 824 1753 2577 y y
13 5 12/06/2002 103 25 16 y y
13 6 13/06/2002 95 15 1015 1684 2699 y y158
Patient 14
Age 21 years
Sex Male
Reason for admission post op, plastics
APACHE II 10
Predicted mortality 5.0%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
14 0 11/06/2002 18 33 25.5 y y
14 1 12/06/2002 50 33 21 y y
14 2 13/06/2002 45 29 16.2 1433 986 2415 y y
14 3 14/06/2002 16 26 11.1
14 4 15/06/2002 42 34 11.9 803 1454 2257159
Patient 15
Age 75 years
Sex Female
Reason for admission pancreatitis
APACHE II 26
Predicted mortality 50.7%
Outcome death
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
15 0 19/06/2002 163 22 15.3 324 2098 2422 y y
15 1 20/06/2002 224 21 14.6 407 1648 2055 y y y y
15 2 21/06/2002 179 17 16.1 547 1972 2519 y y y y
15 3 22/06/2002 174 16 15.7 y y y y
15 4 23/06/2002 174 18 25.4 y y y y
15 5 24/06/2002 201 18 28.4 853 1692 2545 y y y y
15 6 25/06/2002 191 21 31.4 y y y y
15 7 26/06/2002 23.3 y y y y
15 8 27/06/2002 175 32.1 601 1472 2073 y y y y
15 9 28/06/2002 175 22 22.8 615 1386 2001 y y y y
15 10 29/06/2002 179 22 21 y y y y
15 11 30/06/2002 229 22 20.1 y y y y
15 12 01/07/2002 218 22 17.2 659 1998 2653 y y y y
15 13 02/07/2002 233 19 29.3 y y y y160
Patient 16
Age 66 years
Sex Female
Reason for admission medical
APACHE II 30
Predicted mortality 49.3%
Outcome death
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
16 0 23/06/2002 22 12 y y
16 1 24/06/2002 211 26 18 1472 2566 4038 y y
16 2 25/06/2002 27 y y
16 3 26/06/2002 83 26 666 929 1594 y y y161
Patient 17
Age 37 years
Sex Male
Reason for admission post op, abdomen
APACHE II 19
Predicted mortality 48.0%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
17 0 27/06/2002 258 32 24 y y
17 1 28/06/2002 208 26 18 y y
17 2 29/06/2002 193 21 13 y y
17 3 30/06/2002 197 23 15 y y
17 4 01/07/2002 142 23 15 y y
17 5 02/07/2002 119 24 19 y y
17 6 03/07/2002 87 22 18 328 2311 2638 y y
17 7 04/07/2002 90 25 16 1195 y y
17 8 05/07/2002 79 26 17 y y
17 9 06/07/2002 71 26 14 y y
17 10 07/07/2002 63 14 y y
17 11 08/07/2002 70 29 16 317 1094 1415 y y
17 12 09/07/2002 62 29 14 738 1857 2595 y y
17 13 10/07/2002 59 34 20 587 1350 1936 y y
17 14 11/07/2002 43 32 18 648 1375 2023 y y
17 15 12/07/2002 79 32 14 648 831 1479 y y
17 16 13/07/2002 136 33 14 y y
17 17 14/07/2002 174 32 15 y y
17 18 15/07/2002 248 35 19 y y
17 19 16/07/2002 139 30 12 y y
17 20 17/07/2002 23 11 y y162
17 21 18/07/2002 85 32 11 y y
17 22 19/07/2002 68 33 12 y y
17 23 20/07/2002 53 33 12 y y
17 24 21/07/2002 43 34 13 y y
17 25 22/07/2002 28 33 11 533 1487 2023 y y
17 26 23/07/2002 30 35 20 529 1580 2109 y y
17 27 24/07/2002 75 31 18 745 1598 2343 y y
17 28 25/07/2002 48 32 19 507 1494 2001 y y
17 29 26/07/2002 46 34 19 543 1407 1951 y y
17 30 27/07/2002 62 35 20 y y
17 31 28/07/2002 45 35 20 y y
17 32 29/07/2002 31 37 21
17 33 30/07/2002163
Patient 18
Age 55 years
Sex Female
Reason for admission post op, abdomen
APACHE II 18
Predicted mortality 28.9%
Outcome survivor
Patient Day Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated PA 
Cath Inotrope Renal
18 0 08/07/2002 84 16 22 551 799 1350 y y
18 1 09/07/2002 196 18 27 943 1019 1958 y y
18 2 10/07/2002 175 20 17 400 651 1047 y y
18 3 11/07/2002 132 18 11 619 1188 1807 y y y
18 4 12/07/2002 131 20 10 493 875 1368 y y y
18 5 13/07/2002 130 20 8 y y
18 6 14/07/2002 133 22 16 y y
18 7 15/07/2002 174 20 14 y y
18 8 16/07/2002 85 21 10 y y
18 9 17/07/2002 51 22 10 y y164
Patient 19
Age 67 years
Sex Male
Reason for admission post op, neurosurgery
APACHE II 26
Predicted mortality 35.2%
Outcome survivor
Patient Day Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated PA 
Cath Inotrope Renal
19 0 15/08/2002 50 23 y y
19 1 16/08/2002 88 24 y y
19 2 17/08/2002 103 22 y y
19 3 18/08/2002 64 23 y y
19 4 19/08/2002 49 25 468 2160 2627 y y
19 5 20/08/2002 72 26 2307 y y
19 6 21/08/2002 141 26 y y165
Patient 20
Age 65 years
Sex Female
Reason for admission medical
APACHE II 25
Predicted mortality 62.9%
Outcome survivor
Patient Day Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated PA 
Cath Inotrope Renal
20 0 13/08/2002 22 30 17 281 1440 1724 y y
20 1 14/08/2002 78 35 13 407 2052 2458 y y166
Patient 21
Age 84 years
Sex Male
Reason for admission post op, vascular
APACHE II 21
Predicted mortality 57.0%
Outcome death
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
21 0 13/08/2002 y y
21 1 14/08/2002 y y y
21 2 15/08/2002 y y y
21 3 16/08/2002 y y
21 4 17/08/2002 y y
21 5 18/08/2002 y y
21 6 19/08/2002 57 510 1731 2242 y y
21 7 20/08/2002 52 605 1647 2253 y y
21 8 21/08/2002 48 661 1537 2199 y y
21 9 22/08/2002 35 560 1827 2386 y y
21 10 23/08/2002 y y
21 11 24/08/2002 y y
21 12 25/08/2002 y y
21 13 26/08/2002 y y
21 14 27/08/2002 y y
21 15 28/08/2002 y y
21 16 29/08/2002 89 815 1494 2307 y y
21 17 30/08/2002 83 430 1472 1900 y y
21 18 31/08/2002 y y
21 19 01/09/2002 y y
21 20 02/09/2002 87 446 2137 2584 y y167
21 21 03/09/2002 52 462 1676 2138 y y
21 21 04/09/2002 36 542 1572 2113 y y
21 22 05/09/2002 25 530 1858 2390 y y
21 23 06/09/2002 22 602 1548 2149 y y
21 24 07/09/2002 y y
21 25 08/09/2002 y y
21 26 09/09/2002 14 461 1890 2350 y y
21 27 10/09/2002 10 419 1702 2120 y y
21 28 11/09/2002 10 285 1037 1321 y y
21 29 12/09/2002 y y
21 30 13/09/2002 y y
21 31 14/09/2002 y y
21 32 15/09/2002 y y
21 33 16/09/2002 6 310 858 1170 y y
21 34 17/09/2002 6 335 1460 1796 y y
21 35 18/09/2002 6 546 1684 2232 y y
21 36 19/09/2002 6 482 1024 1504 y y
21 37 20/09/2002168
Patient 22
Age 64 years
Sex Male
Reason for admission post op, thoracic
APACHE II 20
Predicted mortality 30.0%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
22 0 09/11/2002 y y
22 1 10/11/2002 y y
22 2 11/11/2002 y y
22 3 12/11/2002 152 391 1063 1454 y y
22 4 13/11/2002 91 455 1444 1897 y y
22 5 14/11/2002 81 497 930 1425 y y
22 6 15/11/2002 68 346 967 1314 y y
22 7 16/11/2002 47 297 1106 1404 y y
22 8 17/11/2002 28 239 1017 1256 y y
22 9 18/11/2002 83 315 1436 1749 y y
22 10 19/11/2002 68 371 1192 1562 y y
22 11 20/11/2002 45 333 1447 1778 y y
22 12 21/11/2002 73 325 1462 1789 y y
22 13 22/11/2002 45 395 1421 1814 y y
22 14 23/11/2002 y y
22 15 24/11/2002 y y
22 16 25/11/2002 y y
22 17 26/11/2002 y y
22 18 27/11/2002 13 346 1406 1753 y y
22 19 28/11/2002 y y
22 20 29/11/2002 9 316 1510 1825 y y169
22 21 30/11/2002 y y
22 22 01/12/2002 y y
22 23 02/12/2002 y y
22 24 03/12/2002 y y
22 25 04/12/2002 y y
22 26 05/12/2002 y y
22 27 06/12/2002 y y
22 28 07/12/2002 y y
22 29 08/12/2002 y y
22 30 09/12/2002 y y
22 31 10/12/2002 y y
22 32 11/12/2002 y y
22 33 12/12/2002 y y170
Patient 23
Age 43 years
Sex Male
Reason for admission post op, plastics
APACHE II 27
Predicted mortality 38.6%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
23 0 17/11/2002 y y y
23 1 18/11/2002 y y Y
23 2 19/11/2002 y y Y
23 3 20/11/2002 y y Y
23 4 21/11/2002 y y Y
23 5 22/11/2002 51 738 1746 2484 y y Y
23 6 23/11/2002 y y Y
23 7 24/11/2002 y y Y
23 8 25/11/2002 y y
23 9 26/11/2002 y y
23 10 27/11/2002 13 533 913 1443 y y
23 11 28/11/2002 y y
23 12 29/11/2002 y y
23 13 30/11/2002 y y
23 14 01/12/2002 y y
23 15 02/12/2002 y y
23 16 03/12/2002 y y
23 17 04/12/2002 y y
23 18 05/12/2002 y y
23 19 06/12/2002 y y
23 20 07/12/2002 y y171
23 21 08/12/2002 y y
23 22 09/12/2002 y y
23 23 10/12/2002 y y
23 24 11/12/2002 y y
23 25 12/12/2002 y y
23 26 13/12/2002 y y
23 27 14/12/2002 y y
23 28 15/12/2002 y y
23 29 16/12/2002 y y
23 30 17/12/2002 y y
23 31 18/12/2002
23 32 19/12/2002172
Patient 24
Age 29 years
Sex Male
Reason for admission pancreatitis
APACHE II 26
Predicted mortality 68.6%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
24 0 12/01/2003 y y Y
24 1 13/01/2003 267 1144 1562 2707 y y
24 2 14/01/2003 196 509 1209 1717 y y
24 3 15/01/2003 146 620 1860 2480 y y
24 4 16/01/2003 134 1219 1574 2793
24 5 17/01/2003 163 997 1775 2771
24 6 18/01/2003 173 732 1457 2188
24 7 19/01/2003 183 943 1691 2635
24 8 20/01/2003 177 821 1958 2779
24 9 21/01/2003 159 806 1733 2537
24 10 22/01/2003 137 693 718 1411173
Patient 25
Age 38 years
Sex Female
Reason for admission post op, abdomen
APACHE II 14
Predicted mortality 30.8%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
25 0 16/01/2003 y y y
25 1 17/01/2003 y y y y
25 2 18/01/2003 y y y y
25 3 19/01/2003 288 371 644 1011 y y y y
25 4 20/01/2003 179 324 659 983 y y
25 5 21/01/2003 114 234 849 1083 y y y
25 6 22/01/2003 66 338 1033 1371 y y
25 7 23/01/2003 y y
25 8 24/01/2003 178 561 1724 2282 y y
25 9 25/01/2003 y y
25 10 26/01/2003 y y
25 11 27/01/2003 188 781 1127 1908 y y
25 12 28/01/2003 139 702 1440 2138 y y
25 13 29/01/2003 109 997 1522 2516 y y
25 14 30/01/2003 87 727 1184 1911 y y
25 15 31/01/2003 y y174
Patient 26
Age 77 years
Sex Female
Reason for admission post op, abdomen
APACHE II 13
Predicted mortality 16.4%
Outcome death
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
26 0 15/02/2003 y y
26 1 16/02/2003 y y
26 2 17/02/2003 y y
26 3 18/02/2003 y y
26 4 19/02/2003 178 209 803 1011 y y
26 5 20/02/2003 y y
26 6 21/02/2003 149 295 889 1184 y y
26 7 22/02/2003 y y
26 8 23/02/2003 y y
26 9 24/02/2003 231 615 1055 1666 y y
26 10 25/02/2003 264 464 1188 1652 y y
26 11 26/02/2003 y y
26 12 27/02/2003 y y175
Patient 27
Age 75 years
Sex Female
Reason for admission pancreatitis
APACHE II 27
Predicted mortality 71.6%
Outcome death
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
27 0 02/03/2003 y y
27 1 03/03/2003 y y
27 2 04/03/2003 337 202 882 1083 y y
27 3 05/03/2003 y y Y
27 4 06/03/2003 y y Y
27 5 07/03/2003 266 259 785 1044 y y Y
27 6 08/03/2003 y y Y
27 7 09/03/2003 y y Y
27 8 10/03/2003 y y y Y
27 9 11/03/2003 y y y Y
27 10 12/03/2003 y y y y
27 11 13/03/2003 y y y y
27 12 14/03/2003 y y y y
27 13 15/03/2003 y y y y
27 14 16/03/2003 y y y y
27 15 17/03/2003 y y y y
27 16 18/03/2003 y y y y
27 17 19/03/2003 y y y
27 18 20/03/2003 y y
27 19 21/03/2003 y y y
27 20 22/03/2003 y y y176
27 21 23/03/2003 y y y
27 23 24/03/2003 y y y y
27 24 25/03/2003 y y y y
27 25 26/03/2003 y y y y
27 26 27/03/2003 y y y y
27 27 28/03/2003 y y y y
27 28 29/03/2003 y y y y
27 29 30/03/2003 y y
27 30 31/03/2003 y y y
27 31 01/04/2003 y y y
27 32 02/04/2003 y y y
27 33 03/04/2003 y y y
27 34 04/04/2003 y y y
27 35 05/04/2003 y y y y
27 36 06/04/2003 y y y y
27 37 07/04/2003 y y y y
27 38 08/04/2003 y y y y
27 39 09/04/2003 y y y y
27 40 10/04/2003 y y y y
27 41 11/04/2003 y y y
27 42 12/04/2003 y y y
27 43 13/04/2003 y y y
27 44 14/04/2003 y y y
27 45 15/04/2003 y y y y
27 46 16/04/2003 y y
27 47 17/04/2003 y y
27 48 18/04/2003 y y y y
27 49 19/04/2003 y y y y
27 50 20/04/2003 y y y
27 51 21/04/2003 y y
27 52 22/04/2003 y y177
27 53 23/04/2003 y y
27 54 24/04/2003 y y
27 55 25/04/2003 y y
27 56 26/04/2003 y y
27 57 27/04/2003 y y
27 58 28/04/2003 y y
27 59 29/04/2003 y y
27 60 30/04/2003 y y
27 61 01/05/2003 y y y
27 62 02/05/2003 y y
27 63 03/05/2003 y y178
Patient 28
Age 82 years
Sex Female
Reason for admission post op, abdomen
APACHE II 22
Predicted mortality 42.1%
Outcome death
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
28 0 12/04/2003 y y
28 1 13/04/2003 y y
28 2 14/04/2003 y y
28 3 15/04/2003 111 425 1166 1591 y y
28 4 16/04/2003 73 389 1004 1393 y y
28 5 17/04/2003 68 371 914 1285 y y
28 6 18/04/2003 y y
28 7 19/04/2003 y y
28 8 20/04/2003 176 572 1393 1965 y y
28 9 21/04/2003 y y
28 10 22/04/2003 y y
28 11 23/04/2003 y y
28 12 24/04/2003 107 626 1141 1767 y y
28 13 25/04/2003 y y
28 14 26/04/2003179
Patient 29
Age 71 years
Sex Male
Reason for admission post op, abdomen
APACHE II 34
Predicted mortality 80.7%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
29 0 15/04/2003 y y y
29 1 16/04/2003 65 407 889 1292 y y y
29 2 17/04/2003 146 403 860 1263 y y y
29 3 18/04/2003 y y y Y
29 4 19/04/2003 y y y Y
29 5 20/04/2003 157 680 1245 1922 y y y Y
29 6 21/04/2003 y y y
29 7 22/04/2003 y y
29 8 23/04/2003 95 439 1105 1544 y y
29 9 24/04/2003 77 439 1310 1749 y y
29 10 25/04/2003 53 378 2113 2491 y y180
Patient 30
Age 30 years
Sex Male
Reason for admission post op, plastics
APACHE II 13
Predicted mortality 16.5%
Outcome death
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
30 0 20/04/2003 390 1163 1303 2466 y y
30 1 21/04/2003 y y
30 2 22/04/2003 y y
30 3 23/04/2003 292 1436 2098 3531 y y
30 4 24/04/2003 232 1022 1566 2588 y y
30 5 25/04/2003 y y
30 6 26/04/2003 y y
30 7 27/04/2003 y y
30 8 28/04/2003 250 475 1260 1735 y y
30 9 29/04/2003 193 759 576 1335 y y y Y
30 10 30/04/2003 y y y Y
30 11 01/05/2003 y y y Y
30 12 02/05/2003 y y y Y
30 13 03/05/2003 y y y Y
30 14 04/05/2003 y y y Y
30 15 05/05/2003 y y y Y181
Patient 31
Age 72 years
Sex Male
Reason for admission post op, vascular
APACHE II 33
Predicted mortality 78.6%
Outcome survivor
Patient Day  Date CRP Albumin WCC HABF PVBF TLBF Intubated Trachy Ventilated
PA 
Cath Inotrope Renal
31 0 31/05/2003 y y
31 1 01/06/2003 y y
31 2 02/06/2003 y y
31 3 03/06/2003 y y
31 4 04/06/2003 154 371 1623 1994 y y
31 5 05/06/2003 168 648 2203 2847 y y182183